<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS202316</article-id><article-id pub-id-type="doi">10.1101/2024.12.13.628333</article-id><article-id pub-id-type="archive">PPR957989</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Eosinophils restrict CRC metastasis by inhibiting pro-tumorigenic SPP1<sup>+</sup> macrophage differentiation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Handler</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Raju</surname><given-names>Deeksha</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Gurtner</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Dalessi</surname><given-names>Tosca</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brügger</surname><given-names>Michael D.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN2">‡</xref></contrib><contrib contrib-type="author"><name><surname>Crepaz</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Esposito</surname><given-names>Cinzia</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Trajanoski</surname><given-names>Zlatko</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Münz</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scharl</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Valenta</surname><given-names>Tomas</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Piscuoglio</surname><given-names>Salvatore</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Fazilaty</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>Isabelle C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute of Experimental Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zürich</institution></institution-wrap>, <city>Zurich</city>, <country country="CH">Switzerland</country></aff><aff id="A2"><label>2</label>Department of Molecular Life Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap>, <city>Zurich</city>, <country country="CH">Switzerland</country></aff><aff id="A3"><label>3</label>Institute of Medical Genetics and Pathology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04k51q396</institution-id><institution>University Hospital Basel</institution></institution-wrap>, <city>Basel</city>, <country country="CH">Switzerland</country></aff><aff id="A4"><label>4</label>Biocenter, Institute of Bioinformatics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pt86f80</institution-id><institution>Medical University of Innsbruck</institution></institution-wrap>, <city>Innsbruck</city>, <country country="AT">Austria</country></aff><aff id="A5"><label>5</label>Department of Gastroenterology and Hepatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01462r250</institution-id><institution>University Hospital Zurich</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap>, <postal-code>8091</postal-code><city>Zurich</city>, <country country="CH">Switzerland</country></aff><aff id="A6"><label>6</label>Comprehensive Cancer Center Zurich, Zurich, Switzerland</aff><aff id="A7"><label>7</label>Laboratory of Cell and Developmental Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/045syc608</institution-id><institution>Institute of Molecular Genetics of the Czech Academy of Sciences</institution></institution-wrap>, <city>Prague</city>, <country country="CZ">Czech Republic</country></aff><aff id="A8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d538656</institution-id><institution>IRCCS Humanitas Research Hospital</institution></institution-wrap>, <city>Milan</city>, <country country="IT">Italy</country></aff><author-notes><fn fn-type="equal" id="FN1"><label>†</label><p id="P1">These authors contributed equally to this work</p></fn><fn id="FN2" fn-type="present-address"><label>‡</label><p id="P2">Current address: Dimericon Therapeutics AG, Bachtobelstrasse 5, 8810 Horgen</p></fn><corresp id="CR1"><label>*</label>Corresponding author: <email>arnold@immunology.uzh.ch</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>17</day><month>01</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>17</day><month>12</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P3">Eosinophils, traditionally associated with allergic responses, have emerged as critical immune modulators in colorectal cancer (CRC). Here, we reveal that eosinophils actively shape the tumor microenvironment and influence metastatic progression. Using comprehensive transcriptomics analysis of human CRC and a murine orthotopic tumor model, we identify a conserved tumor-specific eosinophil signature and activation profile. Despite their declining presence in advanced CRC, eosinophils suppress metastatic dissemination by counteracting the pro-tumorigenic functions of SPP1<sup>+</sup> macrophages – a subset linked to immune exclusion and tumor metastasis. Mechanistically, eosinophils respond to tumor-derived signals and inhibit macrophage differentiation into SPP1<sup>+</sup> cells. Eosinophil depletion exacerbates peritoneal tumor spread. These findings highlight the pivotal role of eosinophils in restraining late-stage CRC progression and unveil a novel eosinophil–macrophage axis as potential therapeutic targets.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P4">Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, primarily due to tumor metastasis to distant sites such as the liver, lungs, and peritoneal cavity (<xref ref-type="bibr" rid="R1">1</xref>). Among these, peritoneal metastases are associated with the poorest prognosis (<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R3">3</xref>). Despite advances in early detection and treatment, late-stage CRC remains largely refractory to immunotherapies, especially in subtypes characterized by a low mutational burden, lack of neoantigens, and poor immunoreactivity (<xref ref-type="bibr" rid="R4">4</xref>). This underscores the urgent need to better understand and target the tumor immune landscape.</p><p id="P5">The tumor microenvironment (TME) consists of a variety of cells that can modulate tumor growth, immune evasion, and metastasis. Among these, eosinophils – a granulocyte subset enriched in mucosal tissues – have recently emerged as intriguing orchestrators of immune responses and tissue homeostasis (<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>). While traditionally associated with allergic diseases, eosinophils are increasingly recognized for their roles in tissue remodeling, immune regulation and anti-tumor immunity. Notably, eosinophil infiltration is often associated with improved prognosis in gastrointestinal malignancies (<xref ref-type="bibr" rid="R7">7</xref>), including CRC, and clinical evidence links their presence to enhanced responses to immune checkpoint blockade therapies (<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R10">10</xref>). However, their precise functions and interactions within the local immune network, particularly during CRC progression and metastasis, remain poorly understood.</p><p id="P6">Recent studies have identified SPP1<sup>+</sup> tumor-associated macrophages (TAMs) as key drivers of metastasis and immune exclusion in CRC (<xref ref-type="bibr" rid="R11">11</xref>). These macrophages are known to interact with cancer-associated fibroblasts to create a tumor-supportive niche (<xref ref-type="bibr" rid="R12">12</xref>). However, whether they also interact with eosinophils and how such interactions might impact metastasis and the tumor immune network remains unexplored.</p><p id="P7">Here, we present a comprehensive investigation of eosinophil dynamics within the TME in human CRC and a murine CRC model. Our findings reveal conserved eosinophil transcriptional programs across species, highlighting their activation and functional reprogramming in tumors. Despite a marked decline in eosinophil frequencies with advancing CRC stages, their activation state increases in more malignant stages, suggesting stage-specific roles in tumor progression. Notably, eosinophils suppress peritoneal metastases by modulating the differentiation of pro-tumorigenic SPP1<sup>+</sup> TAMs. Mechanistically, we show that eosinophils respond to tumor-derived signals, adopt an activated phenotype and prevent SPP1<sup>+</sup> TAMs differentiation. Together, these findings establish a previously unrecognized eosinophil–macrophage axis in CRC progression and metastasis, offering new avenues for therapeutic interventions.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Eosinophils are highly activated across progressive CRC stages in patients</title><p id="P8">To characterize eosinophil dynamics in progressive CRC stages, we quantified MBP-1<sup>+</sup> eosinophils using immunofluorescence staining on human tissue microarrays. In line with our previous findings (<xref ref-type="bibr" rid="R13">13</xref>), eosinophil frequencies decreased markedly as CRC progressed from stage I to stage III (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Notably, their expression of PD-L1 – a marker that we have previously associated with an activated eosinophil subset known as A-Eos (<xref ref-type="bibr" rid="R14">14</xref>) – showed a dichotomic pattern, with lower A-Eos frequencies found in precancerous adenoma stages and higher frequencies observed across all adenocarcinoma stages compared to normal colonic tissue (<xref ref-type="fig" rid="F1">Fig 1B, C</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S1A</xref>).</p><p id="P9">To examine the transcriptional subset composition of human eosinophils in CRC, we performed single-cell RNA sequencing (scRNA-seq) on CD45<sup>+</sup> leukocytes, enriched from tumors and matched normal adjacent tissue (NAT) biopsies from seven CRC patients (<xref ref-type="supplementary-material" rid="SD2">Fig. S1B</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD1">table S1</xref>). Blood eosinophils from six healthy individuals were included as controls. Eosinophil clusters were identified based on the expression of specific marker genes, including <italic>CLC, IL5RA, ADGRE1</italic> and <italic>SIGLEC8</italic> (<xref ref-type="fig" rid="F1">Fig. 1D</xref>) and validated using a mouse eosinophil-specific gene signature, which showed the strongest signal in the annotated eosinophil clusters (<xref ref-type="supplementary-material" rid="SD2">fig. S1C</xref>). Eosinophils from all three sources were integrated (<xref ref-type="supplementary-material" rid="SD2">fig. S1D</xref>). Their quality was consistently high across tissues and clusters (<xref ref-type="supplementary-material" rid="SD2">fig. S1E, F</xref>). Clustering analysis identified two main eosinophil subsets, Eos_H1 and Eos_H2, present in variable proportions across tissues and patients (<xref ref-type="fig" rid="F1">Fig. 1E, F</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S1H</xref>). Notably tumor eosinophils predominantly shifted towards the Eos_H2 cluster compared to eosinophils from normal adjacent tissue, suggesting enrichment of this cluster in CRC (<xref ref-type="fig" rid="F1">Fig. 1F</xref>).</p><p id="P10">Differential gene expression and regulon activity (SCENIC) analysis revealed distinct characteristics for each subset (<xref ref-type="fig" rid="F1">Fig. 1G, H</xref>). The Eos_H1 cluster expressed multiple genes previously reported in human peripheral blood eosinophils, such as <italic>SMPD3, PRSS33, PIK3R6</italic> and <italic>IL5RA</italic> (<xref ref-type="bibr" rid="R15">15</xref>), consistent with its predominant representation among blood eosinophils (<xref ref-type="fig" rid="F1">Fig. 1F</xref>). This subset also showed enrichment for cell adhesion-related genes (<italic>ITGAL, ADGRG5</italic>) and for genes regulated by the transcription factor Interferon Regulatory Factor 1 (IRF1). In contrast, Eos_H2 upregulated the eosinophil activation marker <italic>CD69</italic> (<xref ref-type="bibr" rid="R16">16</xref>) and genes associated with immune regulation and inflammation, including <italic>CCL3, CCL4</italic>, and <italic>TNFAIP3</italic>. Eos_H2 also exhibited strong activation of transcription factors from the NF-κB pathway (<xref ref-type="bibr" rid="R17">17</xref>) (<italic>REL, RELB, NFKB1, NFKB2</italic>) and AP-1 complex (<italic>FOSL1, FOSL2, FOSB</italic>) (<xref ref-type="bibr" rid="R18">18</xref>) (<xref ref-type="fig" rid="F1">Fig. 1G, H</xref>). Together, these results highlight the dynamic changes in eosinophil phenotypes during CRC progression and emphasize their activation via the NF-κB pathway within the TME.</p></sec><sec id="S4"><title>Human eosinophils display tumor-specific gene signatures distinct from those of adjacent colonic tissue</title><p id="P11">To assess whether eosinophils exhibit distinct gene expression profiles within the tumor core compared to normal adjacent tissue, we conducted differential gene expression analysis combined with gene ontology (GO) analysis. Intratumoral eosinophils displayed marked transcriptional differences compared to their counterparts in non-tumor tissue (<xref ref-type="supplementary-material" rid="SD1">Table. S2</xref>), with most upregulated genes associated with the Eos_H2 cluster (<xref ref-type="supplementary-material" rid="SD2">fig. S1G</xref>). Notably, these upregulated genes primarily included cytokines and chemokines (e.g., <italic>CCL3, CCL3L1, CCL4, CCL4L1, CXCL8, CXCR4</italic>), NF-κB signaling (<italic>NFKBIA</italic>), TNF-alpha signaling (<italic>TNFAIP3</italic>), and MHC-I components (<italic>HLA-C, HLA-DRA, B2M</italic>) (<xref ref-type="fig" rid="F1">Fig. 1I</xref>). GO analysis (<xref ref-type="fig" rid="F1">Fig. 1J</xref>) and elevated scores for MHC-I and antigen processing signatures (<xref ref-type="fig" rid="F1">Fig. 1K</xref>) further showed enrichment in these pathways, indicating enhanced immunoregulatory activity. These findings suggest that eosinophils undergo functional reprogramming in the TME, with the Eos_H2 subset representing an activated, inflammation-associated phenotype.</p></sec><sec id="S5"><title>Mouse eosinophils recapitulate human eosinophil recruitment patterns and transcriptional profiles in an orthotopic model of late-stage CRC</title><p id="P12">To explore the functional role of eosinophils in advanced CRC stages, we employed an orthotopic mouse model of tumor organoid transplantation. AKPS colonic tumor organoids – harboring the four most common CRC-driving mutations [<italic>Apc</italic>-LOF (loss of function), <italic>p53-LOF, Kras-GOF</italic> (gain of function), <italic>Smad4-LOF]</italic> (<xref ref-type="bibr" rid="R19">19</xref>) – were successfully engrafted into the colonic mucosa of C57BL/6JRj mice following colonoscopy-guided injection. Within six weeks, tumors developed and progressively expanded through the colonic layers toward the peritoneal cavity (<xref ref-type="fig" rid="F2">Fig. 2A</xref>), mirroring some of the invasive characteristics of late-stage human CRC. Intriguingly, eosinophil infiltration was significantly elevated in precancerous lesions and at an earlier time point (4 weeks) of AKPS tumor development compared to normal adjacent tissue, but stabilized at later stages (6 weeks), where eosinophil numbers were comparable between tumors and normal adjacent tissue (<xref ref-type="fig" rid="F2">Fig. 2B</xref>, <xref ref-type="supplementary-material" rid="SD2">fig. S2A</xref>). Despite this plateau, eosinophil activation markedly increased during malignant transformation, with a higher proportion of activated eosinophils (A-Eos) in advanced AKPS tumors (<xref ref-type="fig" rid="F2">Fig 2C</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S2B</xref>). This contrasts with findings in <italic>Apc</italic><sup>Min/+</sup> adenomas (<xref ref-type="bibr" rid="R20">20</xref>), where eosinophils were more abundant but predominantly consisted of the less activated CD80<sup>-</sup> PD-L1<sup>-</sup> B-Eos subtype (<xref ref-type="bibr" rid="R14">14</xref>) (<xref ref-type="fig" rid="F2">Fig. 2C, D</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S2B</xref>). Overall, these findings align with our observations in CRC patients, where eosinophil frequencies increased in adenomas but decreased in malignant stages while displaying an enhanced activation profile (<xref ref-type="fig" rid="F1">Fig. 1A-C</xref>).</p><p id="P13">To compare the transcriptional profiles of mouse and human CRC eosinophils, we performed scRNA-seq on CD45-enriched leukocytes isolated from AKPS tumors six weeks post-injection. Colons and blood of naïve (control) mice were further included for comparison.</p><p id="P14">The quality of extracted eosinophils was consistent across samples (<xref ref-type="supplementary-material" rid="SD2">fig. S2C</xref>). Newly sequenced cells were projected onto our recently published reference of eosinophil subtypes (<xref ref-type="bibr" rid="R14">14</xref>) using a label transfer approach (<xref ref-type="supplementary-material" rid="SD2">fig. S2D</xref>). Most tumor eosinophils mapped to the A-Eos cluster (<xref ref-type="fig" rid="F2">Fig. 2E</xref>). Of note, eosinophils isolated from the colon and blood of wild-type mice displayed a more differentiated profile compared to those previously reported in <italic>Il5-tg</italic> mice (<xref ref-type="bibr" rid="R14">14</xref>) (<xref ref-type="fig" rid="F2">Fig. 2F</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S2E</xref>), a strain with elevated eosinophil numbers across tissues (<xref ref-type="bibr" rid="R21">21</xref>). Similar to our observations in human CRC, intratumoral eosinophils upregulated multiple transcripts associated with cytokine and chemokine signaling (e.g., <italic>Ccl3, Cxcr4, Il1a, Il1rn, Il1r2, Ccl6</italic>), MHC-I components (<italic>H2-Q7, H2-K1, B2m, H2-D1</italic>), and tissue remodeling (<italic>Vegfa, Mmp9, Thbs1</italic>) (<xref ref-type="fig" rid="F2">Fig. 2G</xref>). These transcriptional changes were further reflected by the enrichment of GO terms such as “Epithelial to mesenchymal transition, Inflammatory response, Interferon gamma response and TNFα signaling via NF-κB”, along with an enhanced “MHC-I and antigen processing” signature score compared to control colon (<xref ref-type="fig" rid="F2">Fig. 2H, I</xref>).</p><p id="P15">To evaluate transcriptional similarities between mouse and human eosinophils and assess potential correspondence between their respective subpopulations, we determined the top differentially expressed genes (DEGs) for each mouse subset and calculated signature scores for human eosinophil clusters. This analysis mapped human Eos_H1 to the mouse B-Eos subset and human Eos_H2 to the mouse A-Eos subset (<xref ref-type="fig" rid="F2">Fig. 2J</xref>), confirming the enrichment of A-Eos in CRC patient tumors (<xref ref-type="fig" rid="F2">Fig. 2K</xref>). Comparison of eosinophil transcripts further revealed interspecies similarities ranging from 23% to 45% across tissues, with the strongest correspondence observed in the A-Eos subset (<xref ref-type="supplementary-material" rid="SD2">fig. S2F, G</xref>). Together, these findings underscore the high concordance between human and mouse eosinophil subsets and highlight the conserved gene expression programs of activated eosinophils within the TME.</p></sec><sec id="S6"><title>Neutrophils and SPP1<sup>+</sup> TAMs accumulate in the TME of human and mouse CRC</title><p id="P16">To further examine the TME of human and mouse CRC, we compared the immune cell composition of tumors and normal adjacent or naive tissue in the respective scRNA-seq dataset from each species. This analysis revealed notable differences in cellular proportions between tumors and control tissues (<xref ref-type="fig" rid="F3">Fig. 3A, B</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S3A-C</xref>). Specifically, eosinophils, mature B cells and plasma cells were reduced within tumors, while neutrophils and SPP1<sup>+</sup> TAMs were significantly increased in both species (<xref ref-type="fig" rid="F3">Fig. 3C</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S3B</xref>). SPP1<sup>+</sup> TAMs were distinguished from other monocytes and macrophages by their high expression of the <italic>SPP1/Spp1</italic> gene (<xref ref-type="supplementary-material" rid="SD2">fig. S3A</xref>). Along with C1QC<sup>+</sup> TAMs, these cells are thought to originate from monocyte-like FCN1<sup>+</sup> cells (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). In the human dataset, monocytes corresponded to the FCN1<sup>+</sup> monocyte-like population (characterized by high <italic>FCN1</italic> expression), while TAMs aligned with the C1QC<sup>+</sup> (high <italic>C1QC, C1QB</italic>) and SPP1<sup>+</sup> (high <italic>SPP1</italic>) subsets. Similarly, in the mouse dataset, we identified C1QC<sup>+</sup> and SPP1<sup>+</sup> TAM populations, although the monocytes showed transcriptional differences, such as low expression of <italic>Fcna</italic> (<xref ref-type="supplementary-material" rid="SD2">fig. S3A</xref>).</p><p id="P17">To explore eosinophil interactions with immune cells in the TME, we performed ligand-receptor prediction analysis using CellPhoneDB (<xref ref-type="bibr" rid="R24">24</xref>). Significant ligand-receptor interactions were quantified, accounting for both eosinophils acting as ligands and as receptors. Interestingly, in both species, eosinophils exhibited the highest number of predicted interactions with the monocyte/macrophage compartment, particularly with SPP1<sup>+</sup> TAMs (<xref ref-type="fig" rid="F3">Fig. 3D</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S3D</xref>). These observations suggest that eosinophil-macrophage interactions may have functional relevance within the TME.</p></sec><sec id="S7"><title><italic>Eosinophil deficiency promotes tumor metastasis and drives the expansion of</italic> SPP1<sup>+</sup> <italic>TAMs</italic></title><p id="P18">To examine the impact of eosinophils on late-stage tumor development and define underlying mechanisms, we injected AKPS organoids into the colon of PHIL mice, a strain genetically engineered to lack mature eosinophils through the expression of diphtheria toxin A under the eosinophil peroxidase (<italic>Epx</italic>) promoter (<xref ref-type="bibr" rid="R25">25</xref>). Six weeks after organoid transplantation, PHIL mice developed smaller primary tumors compared to their wild-type (WT) littermates, with significantly reduced tumor weight and volume (<xref ref-type="fig" rid="F4">Fig. 4A, B</xref>). However, PHIL mice exhibited a marked increase in both the incidence and number of peritoneal tumor dissemination compared to WT mice (<xref ref-type="fig" rid="F4">Fig. 4C, D</xref>), a manifestation of advanced disease association with particularly poor prognosis in patients (<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R3">3</xref>). The scRNA-seq profiling of CD45<sup>+</sup> immune cells from primary and peritoneal tumors in PHIL and WT mice revealed a progressive increase in SPP1<sup>+</sup> TAMs – and a corresponding decrease in eosinophils – from WT control tissues to tumors and ultimately to peritoneal metastases (<xref ref-type="fig" rid="F4">Fig. 4E</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S4B</xref>). In PHIL mice, eosinophil deficiency resulted in a further expansion of SPP1<sup>+</sup> TAMs within tumors, while other macrophage and monocyte subsets were either unaffected or decreased (<xref ref-type="fig" rid="F4">Fig. 4E</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S4C</xref>).</p><p id="P19">Beyond these quantitative changes, SPP1<sup>+</sup> TAMs in PHIL tumors upregulated multiple transcripts linked to pro-tumorigenic activities (<xref ref-type="fig" rid="F4">Fig. 4F</xref>). Consistently, bulk expression of genes associated with angiogenesis (<italic>Vegfa</italic>) and tissue remodeling (<italic>Mmp9</italic>) was significantly enriched in tumors from PHIL mice (<xref ref-type="fig" rid="F4">Fig. 4G</xref>).</p><p id="P20">Together, these findings suggest that, while eosinophils do not limit primary tumor growth in late-stage CRC, they play a critical role in preventing metastatic tumor dissemination by restraining the expansion and pro-tumorigenic activities of SPP1<sup>+</sup> TAMs.</p></sec><sec id="S8"><title>Eosinophils are activated by AKPS tumor cells and restrict the differentiation of SPP1<sup>+</sup> macrophages in vitro</title><p id="P21">Our findings indicate that both murine and human eosinophils are highly activated in the TME of advanced CRC stages (<xref ref-type="fig" rid="F1">Fig. 1B-F</xref> <bold>and</bold> <xref ref-type="fig" rid="F2">fig. 2C-E</xref>). To determine if this activation is influenced by tumor cell-derived factors, we co-cultured eosinophils purified from the spleens of <italic>Il5-tg</italic> mice with either dissociated AKP or AKPS organoids. AKP organoids lack the <italic>Smad4</italic> loss-of-function mutation present in AKPS and represent a less advanced CRC stage. Notably, co-culture with both organoid types shifted eosinophil maturation toward the (CD80<sup>+</sup> PD-L1<sup>+</sup>) A-Eos subset, with higher proportions and increased Siglec-F expression in the AKPS condition (<xref ref-type="fig" rid="F5">Fig. 5A</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S5A</xref>). This activation was accompanied by increased surface expression of CD11b, β2 integrin and CD63, along with decreased granularity (SSC-A), suggesting enhanced adhesion and degranulation (<xref ref-type="fig" rid="F5">Fig. 5B, C</xref>). Remarkably, these features were recapitulated when eosinophils were cultured in the presence of AKPS-derived supernatant (AKPS-sup), indicating that eosinophil activation is driven by soluble tumor-derived factors (<xref ref-type="supplementary-material" rid="SD2">fig. S5B, C</xref>).</p><p id="P22">To explore the molecular mechanisms underlying eosinophil activation, we examined the role of SoxC transcription factors, known regulators of oncoembryonic programs reactivated in CRC (<xref ref-type="bibr" rid="R19">19</xref>). These transcription factors orchestrate embryonic-like pathways that are co-opted by tumor cells to drive growth, immune modulation, and metastasis (<xref ref-type="bibr" rid="R19">19</xref>). Notably, co-culture of eosinophils with SoxC-deficient AKPS organoids significantly reduced the proportion of A-Eos compared to WT AKPS organoids (<xref ref-type="supplementary-material" rid="SD2">fig. S5D</xref>). Further analysis of cytokine-regulated gene signatures using Cytokine Signaling scores (CytoSig) (<xref ref-type="bibr" rid="R26">26</xref>) highlighted IL-33, HMGB1, IL-10 and TGF-β3 as potential mediators of eosinophil activation in both species (<xref ref-type="supplementary-material" rid="SD2">fig. S5E</xref>). The alarmins IL-33 and HMGB1 effectively promoted the maturation of eosinophils into the A-Eos subset <italic>in vitro</italic> (<xref ref-type="supplementary-material" rid="SD2">fig. S5F</xref>). While <italic>Hmgb1</italic> was ubiquitously expressed in the TME, <italic>Il33</italic> expression was restricted to non-immune cells such as fibroblasts, endothelial and epithelial cells (<xref ref-type="supplementary-material" rid="SD2">fig. S5G</xref>). Together, these results underscore the role of tumor-intrinsic factors in modulating eosinophil activation states and functional properties within the TME.</p><p id="P23">We next investigated factors driving the differentiation of SPP1<sup>+</sup> macrophages <italic>in vitro</italic>. Although AKPS-sup induced upregulation of the <italic>Spp1</italic> transcript in bone marrow-derived macrophages (<xref ref-type="fig" rid="F5">Fig. 5D</xref>), it did not significantly increase the expression of the surface markers CD206 and CD13, which have been reported to reliably identify SPP1<sup>+</sup> TAMs (<xref ref-type="bibr" rid="R12">12</xref>) (<xref ref-type="fig" rid="F5">Fig. 5E</xref>) and are specifically upregulated in macrophages from AKPS tumors compared to normal adjacent tissue (<xref ref-type="supplementary-material" rid="SD2">fig. S5H</xref>). In addition, the corresponding transcripts (<italic>Mrc1</italic> for CD206 and <italic>Anpep</italic> for CD13) were expressed within the SPP1<sup>+</sup> TAM cluster in our mouse sequencing dataset (<xref ref-type="supplementary-material" rid="SD2">fig. S3A</xref>). Screening various cytokines revealed that IL-10 and TGF-β strongly induced the SPP1<sup>+</sup> TAM phenotype both transcriptionally, with upregulation of <italic>Spp1, Fn1</italic>, and <italic>Arg1</italic> (<xref ref-type="supplementary-material" rid="SD2">fig. S5I, J</xref>) and at the protein level (<xref ref-type="fig" rid="F5">Fig. 5E</xref>). In contrast, the differentiation of SPP1<sup>+</sup> TAMs was independent of cytokines such as GM-CSF, IL-4, IL-13, TNF-α and IFN-γ (<xref ref-type="supplementary-material" rid="SD2">fig. S5I</xref>). Since AKPS organoid supernatant alone did not significantly promote the SPP1<sup>+</sup> phenotype, the differentiation of this TAM subset may require the presence of additional components beyond tumor-derived factors. Supporting this, while multiple immune and non-immune cell types expressed <italic>Tgfb1/TGFB1</italic> in our scRNA-seq datasets, <italic>Il10/IL10</italic> expression was predominantly restricted to the monocyte/macrophage immune compartment (<xref ref-type="fig" rid="F5">Fig. 5F</xref> <bold>and</bold> <xref ref-type="supplementary-material" rid="SD2">fig. S5K</xref>). Moreover, both <italic>Tgfb1</italic> and <italic>Il10</italic> transcripts were significantly upregulated in AKPS tumors from PHIL mice compared to their wild-type littermates (<xref ref-type="fig" rid="F5">Fig. 5G</xref>), consistent with the higher proportions of SPP1<sup>+</sup> TAMs observed in these mice.</p><p id="P24">To explore the relevance of eosinophil-macrophage interactions, we co-cultured TGF-β- and IL-10-conditioned macrophages with eosinophils. Remarkably, the presence of eosinophils was sufficient to strikingly reduce the frequency of CD206<sup>+</sup> and CD13<sup>+</sup> macrophages, regardless of their prior preconditioning with AKPS-sup (<xref ref-type="fig" rid="F5">Fig. 5H, I</xref>). Furthermore, the expression of LAP (TGF-β1), a marker associated with the pro-tumorigenic activity of macrophages (<xref ref-type="bibr" rid="R27">27</xref>), was markedly decreased in the presence of eosinophils (<xref ref-type="fig" rid="F5">Fig. 5J</xref>). These findings suggest that the differentiation of SPP1<sup>+</sup> TAMs relies on IL-10 and TGF-β signaling, a process which can be effectively counteracted by eosinophils.</p></sec></sec><sec id="S9" sec-type="discussion"><title>Discussion</title><p id="P25">Eosinophils are associated with improved prognosis in several cancer types, particularly those of the GI tract, where their densities have prognostic relevance (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R28">28</xref>). In this study, we present a comprehensive analysis of eosinophil dynamics within the TME, integrating scRNA-seq data from human CRC biopsies and experimental mouse models. Our findings reveal a conserved activation pattern and transcriptional program in tumor-infiltrating eosinophils across species, emphasizing their functional reprogramming within the TME. Notably, we identify and characterize a previously unrecognized eosinophil–macrophage axis that shapes the tumor immune network and plays a pivotal role in CRC progression and metastasis.</p><p id="P26">Recent advances in scRNA-seq have significantly enhanced our understanding of the complexity of myeloid cells within the TME (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). However, granulocytic cells like eosinophils often evade detection by classical transcriptomic methods due to their fragile nature and propensity to degranulate, which hampers effective RNA capture. Using the BD Rhapsody platform, which enables higher detection rates of granulocytes (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R29">29</xref>–<xref ref-type="bibr" rid="R31">31</xref>), we successfully profiled eosinophils at the single-cell level from CRC patient biopsies, including tumors, normal adjacent tissue and healthy blood samples. Our analysis identified two distinct eosinophil clusters that closely mapped the profiles of our previously described A-Eos and B-Eos murine subsets (<xref ref-type="bibr" rid="R14">14</xref>).</p><p id="P27">Our data suggest a progressive activation of blood eosinophils as they transitioned to intestinal tissues and tumors, reflecting their adaptation to the local tissue and tumor microenvironment. Notably, this activation appears to be driven by soluble tumor-derived factors and is influenced by the mutational stage of tumor cells. SoxC transcription factors – key regulators of oncoembryonic programs (<xref ref-type="bibr" rid="R19">19</xref>)– and their downstream effectors, such as HMGB1, collectively promote the emergence of the activated A-Eos phenotype, underscoring their pivotal role in shaping immune dynamics within the TME.</p><p id="P28">Activated eosinophils exhibited distinct transcriptional profiles, including genes associated with NF-κB, TNF-α, and IFN-γ signaling, alongside multiple cytokine and chemokine genes. These findings align with a prior study demonstrating the anti-tumor activity of TNF-α/IFN-γ–activated eosinophils in the metastatic lung (<xref ref-type="bibr" rid="R32">32</xref>). Interestingly, in non-metastatic settings, eosinophils have been shown to control primary tumor growth through direct cytotoxicity or recruitment and activation of T cells (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R33">33</xref>–<xref ref-type="bibr" rid="R36">36</xref>). In contrast, our findings in the AKPS model reveal a distinct role for eosinophils in constraining peritoneal metastases, without consistently impacting primary tumor size. This discrepancy underscores the likely evolving role of eosinophils during CRC progression, transitioning from localized anti-tumor functions in early-stage disease to limiting dissemination in advanced stages.</p><p id="P29">A key finding of our study is the role of eosinophils in regulating SPP1<sup>+</sup> TAMs, a pro-tumorigenic and pro-metastatic macrophage subset implicated in angiogenesis, EMT and immune exclusion (<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R22">22</xref>). Interactions between SPP1<sup>+</sup> TAMs and cancer-associated fibroblasts have been proposed to contribute to the formation of a desmoplastic structure, limiting immune cell infiltration into the tumor core (<xref ref-type="bibr" rid="R37">37</xref>). This dense, fibrotic matrix may also hinder eosinophil recruitment in advanced CRC, explaining their reduced numbers in later stages of the disease. In both human biopsies and the murine AKPS model, SPP1<sup>+</sup> TAMs were enriched within tumors but nearly absent in normal adjacent or control tissue, consistent with their <italic>in situ</italic> differentiation from monocyte-like precursors (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). In eosinophil-deficient PHIL mice, SPP1<sup>+</sup> TAMs accumulated in primary tumors, coinciding with increased peritoneal metastases and a mesenchymal phenotype, as well as upregulation of angiogenesis and tissue remodeling genes like <italic>Vegfa</italic> and <italic>Mmp9</italic>. Notably, the proportion of SPP1<sup>+</sup> TAMs in peritoneal metastases was unchanged in PHIL mice, indicating that eosinophils primarily influence TAM differentiation in primary tumors and act early in the metastatic cascade to prevent invasion and EMT.</p><p id="P30">Our ligand-receptor interaction analysis reveals significant crosstalk between eosinophils and SPP1<sup>+</sup> TAMs within TME. Eosinophils may counteract the tumor-supportive phenotype of SPP1<sup>+</sup> TAMs through interactions involving ICAM-1 and ITGAM/CD11b (<xref ref-type="bibr" rid="R38">38</xref>). Alternatively, eosinophils may release soluble mediators, such as granular proteins, reactive oxygen species, or pro-inflammatory cytokines like IL-1β or TNFα (<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref>). Additionally, eosinophils may preferentially promote the differentiation of C1QC<sup>+</sup> macrophages – an alternative subset derived from tumor-infiltrating monocyte-like precursors that could compete with SPP1<sup>+</sup> TAMs, altering the immune balance within the TME (<xref ref-type="bibr" rid="R23">23</xref>). Further studies are needed to fully elucidate the mechanisms underlying eosinophil interactions with TAMs, and their role in metastatic progression.</p><p id="P31">The prolonged progression to metastatic CRC raises the question of whether eosinophils become systemically activated during this process. While blood eosinophils from eosinophilic esophagitis (EoE) patients were transcriptionally similar to those in healthy individuals (<xref ref-type="bibr" rid="R42">42</xref>), disseminating tumor cells in metastatic CRC may induce systemic transcriptional changes in eosinophils, altering their function in the bloodstream and in distal organs. Larger patient cohorts are required to investigate these dynamics and their implications for CRC progression. However, the fragile nature of eosinophils limits their detection in bulk RNA-seq datasets from public repositories such as TCGA (<xref ref-type="bibr" rid="R43">43</xref>), emphasizing the need for more refined methodologies.</p><p id="P32">In summary, our study highlights the critical role of eosinophils in limiting tumor dissemination in a model of advanced CRC. The conserved transcriptional profiles and activation signatures observed in eosinophils across species strongly support the relevance of these findings in CRC patients. While eosinophil-targeting drugs such as mepolizumab and benralizumab effectively reduce eosinophil levels for severe asthma management (<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R45">45</xref>), the long-term effect of eosinophil depletion on cancer risk, particularly in tumors with prolonged latency such as CRC, remains uncertain (<xref ref-type="bibr" rid="R46">46</xref>). Future therapeutic strategies aimed at selectively activating or recruiting eosinophils to modulate the TME may open new avenues for controlling CRC progression and metastasis.</p></sec><sec id="S10" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S11"><title>Mice</title><p id="P33">C57BL/6J (stock no. 000664) and C57BL/6J-ApcMin/J (stock no.002020) mice were obtained from The Jackson Laboratory. Eosinophil-deficient mice [PHIL (<xref ref-type="bibr" rid="R25">25</xref>)] were obtained from m J.J. Lee (Mayo Clinic, Phoenix, AZ). C57BL/6NRj mice were purchased from Janvier. C57BL/6J mice were used for AKPS organoid injections and non-tumor bearing control mice, PHIL mice were used as the eosinophil-deficient counterpart. All mice were 8-10 week old males at the start of the experiment. <italic>Il5</italic> transgenic (<italic>Il5tg</italic>) mice were described previously (<xref ref-type="bibr" rid="R47">47</xref>), and were used to magnetically sort eosinophils for <italic>in vitro</italic> cell culture experiments. Mice were maintained on a 12h light and 12h dark schedule, and water and chow were provided <italic>ad libitum</italic>.</p></sec><sec id="S12"><title>Animal experimentation</title><p id="P34">All mouse experiments were performed under the approval of the Cantonal Veterinary Office of Zurich, Switzerland and in accordance with Swiss guidelines.</p><sec id="S13"><title>Colonoscopy submucosal injection of AKPS organoids</title><p id="P35">This procedure was adapted from a prior published paper (<xref ref-type="bibr" rid="R48">48</xref>). Upon culturing and passaging of AKPS organoids in Matrigel (Corning) <italic>in vitro</italic>, the organoids were mechanically dissociated, and the equivalent of one 40μl Matrigel dome was resuspended in 50μl OptiMEM (Gibco) to equate to one injection in one mouse. 8-10 week old male mice of a given strain were first anesthetized with isoflurane and placed facing up on a 37°C heating pad. Warm PBS was used to flush fecal content from the colon, before the AKPS organoid solution was injected carefully below the mucosa, using a custom needle, syringe and colonoscope. Observation of a visible injection bubble was noted as an indicator for successful injection in the correct location. The mice were then regularly monitored according to the license, until the experimental or humane endpoint.</p></sec></sec><sec id="S14"><title><italic>In vitro</italic> experimentation</title><sec id="S15"><title>Organoid culturing</title><p id="P36">AKP [<italic>Apc</italic>-LOF (loss of function), <italic>p53</italic>-LOF, <italic>Kras</italic>-GOF (gain of function)] (<xref ref-type="bibr" rid="R19">19</xref>), AKPS [<italic>Apc</italic>-LOF (loss of function), <italic>p53</italic>-LOF, <italic>Kras</italic>-GOF (gain of function), <italic>Smad4</italic>-LOF] (<xref ref-type="bibr" rid="R19">19</xref>) organoids or AKPS SoxC knockout organoids (<xref ref-type="bibr" rid="R19">19</xref>) were cultured in Matrigel (Corning) domes of 50 μl, as previously detailed (<xref ref-type="bibr" rid="R49">49</xref>). The domes were surrounded with complete medium, composed of Advanced DMEM/F12 (Life Technologies) supplemented with 10 mM HEPES (Gibco), 1X GlutaMax (Gibco), 1% penicillin–streptomycin (Gibco), 1X B27 supplement (Gibco), 1X N2 supplement (Gibco) and 1 mM N-acetylcysteine (Sigma-Aldrich). Every 2-3 days, the organoids were split by mechanical dissociation and TrypLE (Gibco, 12604013).</p></sec><sec id="S16"><title>Isolation and culture of splenic eosinophils</title><p id="P37">Spleens of IL-5-tg mice were passed through a 40-μm cell strainer, using a syringe plunger. Ice-cold distilled water was used for red blood cell lysis. Eosinophils were then isolated using anti-SiglecF microbeads (Miltenyi Biotec, 130-118-513), according to manufacturer’s instructions.</p></sec><sec id="S17"><title>Isolation and culture of murine BM-derived macrophages</title><p id="P38">To isolate bone marrow cells, the femur and tibia of mice were flushed using a 23-gauge needle with complete RPMI medium (Gibco, 11875093), and filtered through a 40-μm cell strainer, followed by a red blood cell lysis with ice-cold distilled water for 30 seconds. Cells were then seeded at a density of 0.3x106/ml with complete RPMI medium supplemented with 20ng/ml recombinant M-CSF (BioLegend, 576404), at 37°C. On day 3, more M-CSF supplemented medium was added, and then fully replaced at day 6. On day 7, macrophages were fully differentiated.</p></sec><sec id="S18"><title>In vitro conditioning with supernatant of tumor organoids and cytokines</title><p id="P39">Supernatant of AKPS tumor organoids was prepared by dissociating one organoid dome mechanically. They were cultured in 250μl of complete RPMI medium in a humidified incubator with 5% CO<sub>2</sub>, for 24 h at 37 °C. Eosinophils were magnetically sorted from the spleen of IL-5-tg mice, via positive selection using anti-Siglec-F microbeads (Miltenyi Biotec, 130-118-513), according to the manufacturer’s instructions, or differentiated from bone marrow with mouse SCF (100ng/ml, PeproTech, 250-03) and FLT3-Ligand (100ng/ml, PeproTech, 250-31L) and maintained in complete RPMI supplemented with mouse IL-5 (10 ng ml/1, PeproTech, 215-15). Macrophages were differentiated from the bone marrow of mice and maintained in M-CSF (BioLegend, 576404). Cells were seeded in flat-bottom 48-well plates at a density of 200,000 cells per well (200μl) and conditioned for 16h at 37 °C with cell-free AKPS-supernatant (1:5) or the following mouse cytokines at a concentration of 20ng/μl: TGF-β1 (BioLegend, 763102), IL-10 (PeproTech, 210-10), GM-CSF (PeproTech, 315-03), IL-4 (PeproTech, 214-14), IL-33 (PeproTech, 210-33), TNF (PeproTech, 315-01A), IFNg (PeproTech, 315-05).</p></sec><sec id="S19"><title>Quantitative PCR (qRT–PCR)</title><p id="P40">RNA from either whole tumor tissue or from BM-derived macrophages with conditionings, was isolated using the RNeasy Mini kit (74106 QIAGEN). RNA was isolated according to manufacturer’s instructions, including the optional DNase1 digestion step. cDNA was synthesised with Superscript III reverse transcription (18080-044 QIAGEN). CFX384 Touch Real-Time PCR system (Bio-Rad) was used to measure gene expression, with TaqMan Gene Expression Assays (4331182 Applied Biosystems by Thermo Fisher Scientific) : <italic>Spp1</italic> (Mm00436767_m1), <italic>Tgfb1</italic> (Mm01178820_m1), <italic>Il10</italic> (Mm01288386_m1), <italic>Hprt</italic> (Mm03024075_m1), <italic>Gapdh</italic> (Mm99999915_g1). Relative gene expression was compared to either <italic>Hprt</italic> or <italic>Gapdh</italic> expression, using the 2ΔC(t) calculation.</p></sec></sec><sec id="S20"><title>Flow cytometry</title><sec id="S21"><title>Staining</title><p id="P41">Cells were surface stained in PBS at 4 °C for 30 minutes with fixable viability dye eFluor 780 (Invitrogen, 65-0865-14), and combinations of the following listed antibodies (1:200, all from BioLegend; unless otherwise stated): CD11b BV510 (M1/70, 101263), CD45 BV650 (30-F11,103151), CD80 BV605 (1:100, 16-10A1, 104729), Ly6G Percp-Cy5.5 (1A8, 127616), MHCII AF700 (M5/114.15.2,107622), PD-L1 PE-Cy7 (1:100, 10F.9G2, 124314), SigF BV421 (E50-2440, 552681 BD Biosciences), β2-integrin AF647 (1:200, 101414), CD206 BV711 (141727), CD13 FITC (111005), LAP (TGF-β1) (141405). Samples were acquired on the LSRII Fortessa or Cytek Aurora 5L (Cytek Biosciences)</p></sec><sec id="S22"><title>Data analysis</title><p id="P42">Analysis of flow cytometry data was performed using FlowJo Software. Relative cell frequencies, cell counts, or Mean Fluorescent Intensities (MFIs) were subsequently plotted in graphical formats using GraphPad Prism.</p></sec><sec id="S23"><title>Statistical analysis</title><p id="P43">All statistical analyses were performed using GraphPad Prism. For statistical comparisons of two groups, two-tailed unpaired t-tests were used. For comparisons of more than two groups, a one-way analysis of variance (ANOVA) was used. Differences were considered statistically significant when P &lt; 0.05.</p></sec></sec><sec id="S24"><title>TMAs and quantification</title><sec id="S25"><title>Human tissue microarrays</title><p id="P44">The microarrays CO1505 and BC05002b were obtained from TissueArray.com. Deparaffinized sections were subjected to antigen retrieval in 2.4 mM sodium citrate and 1.6 mM citric acid, pH 6, for 25 min in a steamer. Sections were washed with PBST (0.1% Tween in PBS) and blocked for 1 h at room temperature in a blocking buffer (5% BSA, 5% heat inactivated normal goat serum in PBST). Slides were incubated overnight at 4 °C with the following primary antibodies (1:100, in blocking buffer): mouse anti-human MBP-1 (BMK-13, MCA5751 Bio-Rad) and rabbit anti-human PD-L1 (E1L3N, 13684S Cell Signaling). After washing three times with PBST, the following secondary antibodies were added (1:400 in blocking solution) to the slides for 1 h at room temperature: AlexaFluor goat anti-rabbit 594 and AlexaFluor goat anti-mouse 647 (Thermo Fisher Scientific). Slides were mounted in Prolog Gold (P36930 Invitrogen) and imaged on a Nikon Ti2-E inverted microscope, equipped with CrestOptics X-Light v3 confocal disk unit, Lumencor Celesta lasers and Photometrics Kinetix camera.</p></sec><sec id="S26"><title>Image analysis for quantification</title><p id="P45">Only intact cores were counted. ND files were imported in Imaris 9.6.0 and spot objects were created in the green (MBP-1) and red (PD-L1) channels separately (estimated XY diameter = 7 μm, estimated Z diameter = 4 um, quality filter &gt; 6). To quantify the co-expression of PD-L1 and MBP-1, the distance of each spot in the green channel to the nearest spot in the red channel was computed. Green spots (eosinophils) with distance to red spots &lt; 4 μm were considered as active eosinophils (A-Eos) (co-expressing PD-L1 and MBP-1). Green spots with distance to red spots &gt; 4 μm were considered basal eosinophils (B-Eos). The active-to-basal ratio was then computed by dividing the number of active by the number of basal eosinophils in each core. To quantify eosinophils percentage in the core, a spot object in the blue (DAPI) channel was created (estimated XY diameter = 7 μm, estimated Z diameter = 4 um, quality filter &gt; 6) and DAPI cells were counted.</p></sec></sec><sec id="S27"><title>Human sample collection and ethical statement</title><sec id="S28"><title>Collection of human biopsies (normal mucosa and tumor)</title><p id="P46">Adjacent normal mucosa and tumor tissues were collected from CRC patients with informed written consent, and under approval of the Ethics Committee of Basel, EKBB, no. 2019-02118. Fresh tissues were kept in DMEM (Life Technologies) containing 10% FBS, 1% penicillin–streptomycin (P0781 Sigma) on ice, until processing.</p></sec><sec id="S29"><title>Blood collection</title><p id="P47">Blood was collected from healthy donors with informed written consent and under approval of the cantonal ethical committee of Zurich, Switzerland (BASEC-Nr.: 2019-00837).</p></sec></sec><sec id="S30"><title>Tissue dissociation for scRNAseq</title><sec id="S31"><title>Mouse AKPS tumors</title><p id="P48">Tumors and metastases were collected at ethical endpoints and then a single cell suspension was prepared using the following protocol. AKPS tumors were cut into small pieces and digested in a shaking incubator at 37°C in RPMI 1640 supplemented with 10% FBS and 100 U/ml penicillin/streptomycin (P0781 Sigma), containing type IV collagenase (C5138 Sigma) and 0.05 mg/ml DNase I (10104159001 Roche). A single cell suspension was then obtained by pushing through a 70-μm cell strainer.</p></sec><sec id="S32"><title>Colon from non-tumor bearing mice</title><p id="P49">Colons from non-tumor bearing mice were collected and cleaned, removing mesenteric fat and intestinal contents. The colons were then cut open lengthwise and washed in PBS, before being cut into 1-2 cm pieces. The colonic tissue was then immersed in falcon tubes containing wash buffer (2% BSA, 100 U ml–1 penicillin–streptomycin (P0781 Sigma) and 5 mM EDTA in HBSS) and placed in a 37°C shaking incubator for 2 x 25 min washes. The wash buffer was replaced in between washes. The tissues were subsequently rinsed with PBS, and then digested 37°C for 50 min in RPMI 1640 supplemented medium, containing 15 mM HEPES (H0887 Sigma), 500 U/ml type IV (C5138 Sigma) and type VIII (C2139 Sigma) collagenase, and 0.05 mg/ml DNase I (10104159001 Roche). Cell suspensions were then obtained by passing the digested mix through a 70-μm cell strainer, followed by centrifugation and layering onto a 40/80% Percoll (17089101 Cytiva) gradient. The interphase was subsequently collected and washed in PBS.</p></sec><sec id="S33"><title>Blood from non-tumor bearing mice</title><p id="P50">Blood from non-tumor bearing mice was collected via terminal cardiac puncture. Red blood cells were subsequently lysed using distilled cold water for 30 s.</p></sec><sec id="S34"><title>Human CRC biopsies (tumor and NAT)</title><p id="P51">Fat tissue and visible blood vessels were removed before tissue processing. Fresh normal mucosa and CRC tissue were washed three times with ice-cold PGA solution (HBSS, 1% penicillin–streptomycin (P0781 Sigma). Tissues were then shaken into 25 mL of DTT solution (PGA solution; 0.1M DTT (Thermo Scientific, 707265ML) at 300 rpm for 15 min at RT. After removal of the DTT solution, samples were washed twice with PGA solution and incubated twice for 15 min at 300 rpm at 37 °C in EDTA solution (PGA solution; 1M HEPES (H0887 Sigma); 0.5M EDTA). Tissues were cut into small pieces, washed twice with PGA solution and digested with collagenase A (10103578001 Roche) at 0.16 U/mL and DNase I (10104159001 Roche) at 2 mg/mL in complete RPMI 1640 medium (containing 10% FBS and 1% penicillin–streptomycin (P0781 Sigma)) for 45 min at 37 °C in the GentleMACS dissociator (program: 37C_h_TDK_2). After digestion, cells were filtered through a 100 μm strainer and spun at 200g for 3 min.</p></sec><sec id="S35"><title>Human blood processing</title><p id="P52">Blood was resuspended in 10mL PBS and spun at 400g for 5 min.</p></sec></sec><sec id="S36"><title>Cell enrichment using magnetic beads</title><p id="P53">For colonic tissues (AKPS mouse tumors, colon from non-tumor bearing mice, peritoneal metastases, human biopsies) cells were subjected to a CD45<sup>+</sup> enrichment using anti-CD45 microbeads (mouse: 130-052-301, human: 130-045-801, Miltenyi Biotec) according to the manufacturer’s instructions. Blood samples (blood from healthy individuals, blood from non-tumor bearing mice) were positively enriched for eosinophils using a PE anti-mouse Siglec-F antibody (562068, BD Biosciences; E50-2440) and anti-PE microbeads (130-042-401, Miltenyi Biotec) for mice; and MACSxpress Whole Blood Eosinophil Isolation Kit (130-104-446, Miltenyi Biotec) for human. After the enrichment cells were subjected to morphological examination with Trypan Blue before proceeding for scRNA-seq.</p></sec><sec id="S37"><title>Single cell RNA sequencing - experimental</title><sec id="S38"><title>Cell hashing to pool multiple samples</title><p id="P54">In order to pool multiple samples for sequencing, single cells of individual samples were labeled with sample tags (633781 BD Human Single-Cell Multiplexing Kit, 633793 BD Mouse Single-Cell Multiplexing Kit) following the manufacturer’s instructions. In brief, 10<sup>6</sup> cells from each sample were resuspended in a staining buffer (PBS with 1% BSA, 1% EDTA) containing the respective sample tag. After an incubation of 20 min at room temperature, cells were washed twice with a staining buffer, using a centrifugation at 400g for 5 min, before resuspension in 1 ml staining buffer for counting. From each sample, approximately 10-20,000 cells from up to 4 sample tags were pooled, resulting in 60-80,000 cells, for single cell capture.</p></sec><sec id="S39"><title>Single cell capture, library preparation and sequencing</title><p id="P55">Pooled samples were centrifuged a last time at 400g for 5 min, before their resuspension in 650 μl BD Sample Buffer supplemented with a cocktail of Rnase inhibitors (1:1,000 SUPERase 20 U μl<sup>-1</sup>, AM2694 Thermo Fisher Scientific; NxGen Rnase Inhibitor 40 U μl<sup>-1</sup>, 30281-2 Lucigen). Cells were then loaded on a BD Rhapsody cartridge and their RNA was captured with the BD Rhapsody Express Single-Cell Analysis System following the manufacturer’s instructions (BD Biosciences) using version 1 beads for the mouse colonic samples and the enhanced beads for the remaining samples. cDNA and sample tag libraries were prepared with the BD Rhapsody Whole Transcriptome Analysis Amplification Kit (633801 BD Biosciences) following the mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol (BD Biosciences). The quality and quantity of the resulting libraries were then analyzed using a Qubit Fluorometer with Qubit dsDNA HS Kits (Q32851 Thermo Fisher Scientific) and a TapeStation 4200 system with HS D5000 tapes and reagents (5067-5592 Agilent Technologies). Paired-end sequencing was performed on NovaSeq6000 and NovaSeqX systems (Illumina) using NovaSeq 6000 SP100 Reagents (100 cycles) and NovaSeqX Reagents. For v1 beads 20%, and for the enhanced beads 1% PhiX were spiked in for sequencing. Sequencing depth was around 20,000 reads/cell for the WTA library and 500-1000 reads/cell for the sample tag library.</p></sec></sec><sec id="S40"><title>Single cell RNA sequencing - data analysis</title><sec id="S41"><title>Pre-processing, normalization and clustering</title><p id="P56">Raw sequencing data was demultiplexed using Bcl2fastq (v2.20.0.433, Illumina). Resulting Fastq files were then uploaded to the Seven Bridges Genomics platform and further processed using the BD Rhapsody™ WTA analysis pipeline (v1.12.1) with default settings for the mouse samples. For the human samples the Exact Cell Count parameter was set to 100,000 to increase the chance of identifying eosinophils which often do not get identified because of their low number of expressed genes. For gene mapping a previously generated STAR index with gene code GRCm38 v25 for mouse and GRCh38 v43 for human data was generated using STAR (<xref ref-type="bibr" rid="R50">50</xref>) (v2.5.2b). Downstream analysis was done in R (v4.3) using the Seurat package (v5.1.0) (<xref ref-type="bibr" rid="R51">51</xref>) if not specified otherwise. Cells with fewer than 200 gene features, more than 5000 gene features (only for mouse data, no upper cutoff for human data) and more than 25 % of genes mapped to mitochondrial genes were removed. Additionally, cell free RNA contaminations were estimated and removed using the bioconductor package decontX (<xref ref-type="bibr" rid="R52">52</xref>) (v1.0.0, <ext-link ext-link-type="uri" xlink:href="https://github.com/campbio/decontX">https://github.com/campbio/decontX</ext-link>)<sub>;</sub> which applies a Bayesian model. All samples were log normalized and scaled using the Seurat functions ‘NormalizeData’ and ‘ScaleData’ while regressing out nFeature_RNA, nCount_RNA and percent.mt. The top 2,000 variable features were used for principal component analysis (PCA) which was followed by the shared nearest neighbor clustering using the Louvain algorithm with multi level refinement. The clustering was then visualized by UMAPs. First clusters were analyzed at low resolutions between 0.1 - 0.5 for broad cell type annotations followed by sub-clustering of individual clusters using the Seurat Function ‘FindSubClusters’ to annotate cellular subtypes at resolutions between 0.1 - 0.5.</p></sec><sec id="S42"><title>Integration of datasets</title><p id="P57">Colonic samples were combined per species and blood samples from healthy individuals were pooled separately. In all cases, the data was integrated using the fast mutual nearest neighbors (FastMNN) approach (‘FastMNNIntegration’ Seurat function). The blood data from non-tumor bearing mice was clustered separately without any batch effect correction. Eosinophils from the human data (colonic and blood derived) were extracted from the annotated data and re-integrated (FastMNN) and re-clustered. Eosinophils from the mouse data were also extracted from annotated data, however, in this case single eosinophils were integrated with a previously published reference (<xref ref-type="bibr" rid="R14">14</xref>) (non-tumor bearing <italic>Il5-</italic>transgenic mice; eosinophils from colon, blood and bone marrow) using the label transfer approach from the Seurat package. Thereby, the query cells were projected onto the reference UMAP of annotated cells whose label was then transferred to the query cells.</p></sec><sec id="S43"><title>Cell type annotation and their comparison between conditions</title><p id="P58">In all cases clusters were removed if their number of gene features was very small with simultaneously high percentage of genes mapped to mitochondria (low quality), or if they expressed genes from various different cell types (mixed). For automatic annotation the package SingleR (<xref ref-type="bibr" rid="R53">53</xref>) (v2.4.1, <ext-link ext-link-type="uri" xlink:href="https://github.com/dviraran/SingleR">https://github.com/dviraran/SingleR</ext-link>) was used with the murine ImmGen (<xref ref-type="bibr" rid="R54">54</xref>) (Immunological Genome Project) and the human NovershternHematopoieticData (<xref ref-type="bibr" rid="R55">55</xref>) data as references, loaded via the celldex (<xref ref-type="bibr" rid="R53">53</xref>) (v1.12.0, <ext-link ext-link-type="uri" xlink:href="https://github.com/SingleR-inc/celldex">https://github.com/SingleR-inc/celldex</ext-link>) package.</p><sec id="S44"><title>Mouse CD45<sup>+</sup> data</title><p id="P59">Clusters were first annotated broadly using the automated cell type annotation approach. Subtypes were then annotated based on known marker genes, their DEGs and the following references: monocytes/macrophages (<xref ref-type="bibr" rid="R56">56</xref>), T cells (<xref ref-type="bibr" rid="R57">57</xref>) and ILCs (<xref ref-type="bibr" rid="R58">58</xref>). Additionally, DEGs were cross-checked in the PangloaDB (<xref ref-type="bibr" rid="R59">59</xref>) database webtool (<ext-link ext-link-type="uri" xlink:href="https://panglaodb.se">https://panglaodb.se</ext-link>).</p></sec><sec id="S45"><title>Mouse blood data</title><p id="P60">Cell clusters were annotated based on automated annotation and investigation of their DEGs.</p></sec><sec id="S46"><title>Mouse eosinophilic data</title><p id="P61">Blood and colonic eosinophils were annotated based on the resulting predicted label from label transfer.</p></sec><sec id="S47"><title>Human CD45<sup>+</sup> data</title><p id="P62">Clusters were annotated based on DEGs, known marker genes and previously published single cell data references from human cancers (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R61">61</xref>). The annotation of the eosinophils was confirmed using a module score computation approach (see details in a later section ‘<xref ref-type="sec" rid="S55">Module score computation approach</xref>’).</p></sec><sec id="S48"><title>Human blood data</title><p id="P63">Cell clusters were annotated based on DEGs and automatic annotation results. The annotation of the eosinophils was confirmed using a module score computation approach (see details in a later section ‘<xref ref-type="sec" rid="S55">Module score computation approach</xref>’).</p></sec><sec id="S49"><title>Human eosinophilic data</title><p id="P64">Eosinophil subtypes were annotated based on the module score approach (see details in a later section ‘<xref ref-type="sec" rid="S55">Module score computation approach</xref>’).</p></sec><sec id="S50"><title>Statistical analysis to assess differences in cell type proportions between conditions</title><p id="P65">Only CD45 positive cells were used for this analysis. Statistical differences between conditions were estimated using the R package scProportionTest (<xref ref-type="bibr" rid="R62">62</xref>) (v0.0.0.9000, <ext-link ext-link-type="uri" xlink:href="https://github.com/rpolicastro/scProportionTest">https://github.com/rpolicastro/scProportionTest</ext-link>).</p><p id="P66">Thereby, a permutation test was applied to compute p-values, which were further corrected using Benjamini-Hochberg (FDR, false discovery rate). The magnitude of enrichment or depletion for each cell type was calculated via bootstrapping returning a confidence interval (log2FD, log2 fold difference). Changes between conditions were significant if FDR p-values were smaller than 0.05 and the log2FD was larger than 0.5 or smaller than -0.5.</p></sec></sec><sec id="S51"><title>Differential gene expression (DEG) analysis</title><p id="P67">For DEG analysis the Seurat functions ‘FindAllMarkers’ and ‘FindMarkers’ with min.pct = 0.25 and logfc.threshold = 0.25) were used on normalized data. Thereby a non-parametric Wilcoxon Rank-Sum test with Bonferroni correction was applied.</p></sec><sec id="S52"><title>Gene set enrichment analysis (GSEA)</title><p id="P68">DEGs between conditions following the approach explained above were used for gene set enrichment analysis (GSEA) using the R package FGSEA (<xref ref-type="bibr" rid="R63">63</xref>) (v1.28.0, <ext-link ext-link-type="uri" xlink:href="https://github.com/ctlab/fgsea">https://github.com/ctlab/fgsea</ext-link>). To pre-rank, DEGs were sorted in decreasing order using the following formula -log10(p-val_adj)/sign(avg_log2FC), thereby taking the adjusted p-value and the log2 fold change (log2FC) into account. Via null hypothesis testing for each gene ontology (GO) term a normalized enrichment score was calculated and p-values were adjusted using the Benjamaini Hochberg (BH) approach. The genes for the GO terms were extracted from the following Molecular Signature Databases (MSigDB) (<xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R65">65</xref>): Reactome, Hallmarks, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Biological Process (BP).</p></sec><sec id="S53"><title>Analysis of regulon activity with SCENIC</title><p id="P69">SCENIC (<xref ref-type="bibr" rid="R66">66</xref>) (v1.3.1, <ext-link ext-link-type="uri" xlink:href="https://github.com/aertslab/SCENIC">https://github.com/aertslab/SCENIC</ext-link>) was applied between clusters from the human eosinophilic dataset using default parameters with the following approach: filtering of the gene expression matrix [minCountsPerGene = 3*.01*ncol(exprMat); minSamples = ncol(exprMat)*.01], computation of correlations with the function ‘runCorrelation’, transcription factor target inference using GENIE3 (<xref ref-type="bibr" rid="R67">67</xref>) (v1.24.0, <ext-link ext-link-type="uri" xlink:href="https://github.com/aertslab/GENIE3">https://github.com/aertslab/GENIE3</ext-link>) and calculation of gene regulatory networks (GRNs) and their activity scores for each cell with AUCell (<xref ref-type="bibr" rid="R66">66</xref>) (v1.24.0, <ext-link ext-link-type="uri" xlink:href="https://github.com/aertslab/AUCell">https://github.com/aertslab/AUCell</ext-link>).</p></sec><sec id="S54"><title>Comparison of mouse and human eosinophils</title><p id="P70">To quantify the number of shared and unique genes between mouse and human eosinophils all genes with counts larger than zero were counted and compared in a Venn diagram using the R package ggVennDiagram (<xref ref-type="bibr" rid="R68">68</xref>, <xref ref-type="bibr" rid="R69">69</xref>) (v1.5.2). Genes where no orthologues were found between the species were dropped and not considered.</p></sec><sec id="S55"><title>Module score computation approach</title><p id="P71">This approach was used to compute the ‘MHC-I and antigen processing’ score, the general eosinophilic and eosinophilic subtype scores. For the general score the top 50 DEGs expressed in eosinophils from annotated colonic mouse cells and for the subtype score the top 50 DEGs between subtypes from wild type eosinophils of the tumor, colon and blood (non-tumor bearing mice) were used. The genes were converted to human gene symbols using the ‘convert_orthologs’ from the orthogene (<xref ref-type="bibr" rid="R70">70</xref>) Bioconductor package (v1.8.0) and used for the score calculation. For the ‘MHC-I and antigen processing score’ genes from the gene ontology term GO:0002474 were used (mouse: <italic>H2-D1, H2-Q7, H2-K1, H2-T23, H2-Q4, Tap1, Tapbp, B2m, Psmb8, Psme1, Psmb9, Calr, Psmb10, Ncf1, Fcer1g</italic>; human: TAP1, TAPBP, B2M, PSMB8, PSMB1, PSMB9, CALR, PSMB10, NCF1, FCER1G, HLA-A, HLA-C, HLA-B). The module scores were calculated using the Seurat function ‘AddModuleScore’ where the average expression of the module genes was subtracted by the aggregated expression of random background genes. Significant differences between conditions were then identified using a two-sided Wilcoxon Rank-Sum test (function ‘wilcox.test’ from the stats R package).</p></sec><sec id="S56"><title>Prediction of ligand-receptor interactions with CellPhoneDB</title><p id="P72">The Python package CellPhoneDB (<xref ref-type="bibr" rid="R24">24</xref>) (v5, <ext-link ext-link-type="uri" xlink:href="https://github.com/ventolab/CellphoneDB">https://github.com/ventolab/CellphoneDB</ext-link>) was applied to the tumor mouse and human data using Python v3. As inputs the gene count matrix and a metadata file containing the cell type annotations were used. The mouse gene symbols were converted to human symbols because only these can be detected with the CellPhoneDB algorithm. For the conversion the biomaRt (<xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R72">72</xref>) (v2.58.2) R package was used. For each species we run CellPhoneDB separately using the ‘cpdb_statistical_analysis_method’ with default parameters. In short, for each combination of cell clusters the mean expression of ligands and receptors that are present in the CellPhoneDB repository was calculated. To statistically test their significance a null distribution of means was created from randomly permuted cluster labels. To calculate the total number of interactions from eosinophils and any other cell type we calculated the sum of all interactions going both directionalities (ligand - receptor and receptor - ligand) using the mean values. Mean values were also used to plot L-R interactions between eosinophils and SPP1<sup>+</sup> TAMs.</p></sec><sec id="S57"><title>CytoSig analysis</title><p id="P73">The average log fold change from significant DEGs (p value adjusted ≤ 0.05, average log2FC &gt; 0.25) between two conditions were used for the web based tool CytoSig (<ext-link ext-link-type="uri" xlink:href="https://cytosig.ccr.cancer.gov/">https://cytosig.ccr.cancer.gov/</ext-link>) (<xref ref-type="bibr" rid="R26">26</xref>). This algorithm was using a two-sided Wilcoxon Rank-Sum test with Benjamini Hochberg p-value adjustment to calculate the predicted response to signaling molecules (chemokines, cytokines and growth factors). The CytoSig database only contains human gene symbols, therefore the mouse gene symbols first needed to be converted using the biomaRt (<xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R72">72</xref>) (v2.58.2) R package for the mouse data.</p></sec><sec id="S58"><title>Plotting</title><p id="P74">For plotting ggplot2 (<xref ref-type="bibr" rid="R73">73</xref>) (v3.5.1), pheatmap (v1.0.12, <ext-link ext-link-type="uri" xlink:href="https://github.com/raivokolde/pheatmap">https://github.com/raivokolde/pheatmap</ext-link>) and ComplexHeatmap (<xref ref-type="bibr" rid="R74">74</xref>) (v2.18.0) were used.</p></sec></sec><sec id="S59"><title>Schematic drawings</title><p id="P75">Schematic drawings were generated with Biorender.com.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Tables</label><media xlink:href="EMS202316-supplement-Supplemental_Tables.pdf" mimetype="application" mime-subtype="pdf" id="d26aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplemental Figures</label><media xlink:href="EMS202316-supplement-Supplemental_Figures.pdf" mimetype="application" mime-subtype="pdf" id="d26aAcEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S60"><title>Acknowledgments</title><p>We thank G. De Lange, J. King, M. Nater, V. Marteau, I. Gonzalez-Perez, E. Roussel, P. Krebs, C. Schneider, M. van den Broek and A. Müller for technical support and ideas; E. A. Jacobsen and the Mayo Clinic for providing PHIL mice. We also thank M. Böni for naive blood collection and D. Liberati for helping provide the human samples. We also extend our gratitude to Konrad Basler for his support and for providing the resources necessary for the development of the mouse tumor model. We are also thankful to the Functional Genomic Center Zurich and the Laboratory Animal Services Center (LASC) of the University of Zurich for their help.</p><sec id="S61"><title>Funding</title><p>This work was supported by the following funding sources. I.C.A. was supported by the Eccellenza Professorial Fellowship from the Swiss National Science Foundation (PCEFP3_187021), a Consolidator Grant from the Swiss National Science Foundation (TMCG-3_213857) and a Grant from the Vontobel Foundation (1120/2022). I.C.A. and M.S. were additionally supported by a TANDEM grant from the ISREC Foundation. H.F. was supported by the Forschungskredit of the University of Zürich FK-21-119) and a grant from the University and Medical Faculty of Zürich and the Comprehensive Cancer Center Zürich. T.V. was supported by the Project National Institute for Cancer Research, Programme EXCELES (LX22NPO5102), Funded by the European Union—Next Generation EU. T.D. was supported by the Swiss 3R Competence Center Grant (3RCC) (DP-2022-003) and a grant from the Julius Klaus Stiftung.</p></sec></ack><sec id="S62" sec-type="data-availability"><title>Data and materials availability</title><p id="P76">All data associated with this study are present in the paper or the <xref ref-type="supplementary-material" rid="SM">Supplementary Materials</xref>. scRNA-seq data have been submitted to GEO under accession number GSE282765. The analysis code used for this study can be found in the GitHub repository: <ext-link ext-link-type="uri" xlink:href="https://github.com/Arnold-Lab-UZH/Eosinophils_in_CRC">https://github.com/Arnold-Lab-UZH/Eosinophils_in_CRC</ext-link>.</p></sec><fn-group><fn id="FN3" fn-type="con"><p id="P77"><bold>Author contributions:</bold> D.R., A.G., T.D., M.B., D.C., T.V. and H.F. performed the experiments and analysis. A.G., D.R., K.H. and I.C.A. designed the experiments. C.E., C.M., M.S., S.P., T.V. and H.F. provided critical resources and materials. K.H., D.R. and I.C.A. wrote the manuscript. I.C.A conceived and supervised the project.</p></fn><fn id="FN4" fn-type="conflict"><p id="P78"><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franko</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Meyers</surname><given-names>JP</given-names></name><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name><name><surname>Punt</surname><given-names>CJA</given-names></name><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Tebbutt</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Analysis and Research in Cancers of the Digestive System (ARCAD) Group, Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><fpage>1709</fpage><lpage>1719</lpage><pub-id pub-id-type="pmid">27743922</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kranenburg</surname><given-names>O</given-names></name><name><surname>van der Speeten</surname><given-names>K</given-names></name><name><surname>de Hingh</surname><given-names>I</given-names></name></person-group><article-title>Peritoneal metastases from colorectal cancer: Defining and addressing the challenges</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><elocation-id>650098</elocation-id><pub-id pub-id-type="pmcid">PMC8010649</pub-id><pub-id pub-id-type="pmid">33816304</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2021.650098</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><name><surname>Skora</surname><given-names>AD</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><name><surname>Azad</surname><given-names>NS</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Biedrzycki</surname><given-names>B</given-names></name><etal/></person-group><article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="pmcid">PMC4481136</pub-id><pub-id pub-id-type="pmid">26028255</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Ignacio</surname><given-names>A</given-names></name><name><surname>McCoy</surname><given-names>KD</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name></person-group><article-title>The emerging roles of eosinophils in mucosal homeostasis</article-title><source>Mucosal Immunol</source><year>2020</year><volume>13</volume><fpage>574</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">32157190</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurtner</surname><given-names>A</given-names></name><name><surname>Crepaz</surname><given-names>D</given-names></name><name><surname>Arnold</surname><given-names>IC</given-names></name></person-group><article-title>Emerging functions of tissue-resident eosinophils</article-title><source>J Exp Med</source><year>2023</year><volume>220</volume><pub-id pub-id-type="pmcid">PMC10276195</pub-id><pub-id pub-id-type="pmid">37326974</pub-id><pub-id pub-id-type="doi">10.1084/jem.20221435</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>SCS</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Umansky</surname><given-names>V</given-names></name></person-group><article-title>Opposing roles of eosinophils in cancer</article-title><source>Cancer Immunol Immunother</source><year>2019</year><volume>68</volume><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="pmcid">PMC11028063</pub-id><pub-id pub-id-type="pmid">30302498</pub-id><pub-id pub-id-type="doi">10.1007/s00262-018-2255-4</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huland</surname><given-names>E</given-names></name><name><surname>Huland</surname><given-names>H</given-names></name></person-group><article-title>Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells</article-title><source>J Cancer Res Clin Oncol</source><year>1992</year><volume>118</volume><fpage>463</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">1618895</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blomberg</surname><given-names>OS</given-names></name><name><surname>Spagnuolo</surname><given-names>L</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Voorwerk</surname><given-names>L</given-names></name><name><surname>Isaeva</surname><given-names>OI</given-names></name><name><surname>van Dyk</surname><given-names>E</given-names></name><name><surname>Bakker</surname><given-names>N</given-names></name><name><surname>Chalabi</surname><given-names>M</given-names></name><name><surname>Klaver</surname><given-names>C</given-names></name><name><surname>Duijst</surname><given-names>M</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><etal/></person-group><article-title>IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>106</fpage><lpage>123</lpage><elocation-id>e10</elocation-id><pub-id pub-id-type="pmid">36525971</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>P</given-names></name><name><surname>Kuai</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils</article-title><source>Int J Cancer</source><year>2020</year><volume>146</volume><fpage>1730</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">31840816</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name></person-group><article-title>ANGPTL2+cancer-associated fibroblasts and SPP1+macrophages are metastasis accelerators of colorectal cancer</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><elocation-id>1185208</elocation-id><pub-id pub-id-type="pmcid">PMC10483401</pub-id><pub-id pub-id-type="pmid">37691929</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1185208</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xun</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><elocation-id>1742</elocation-id><pub-id pub-id-type="pmcid">PMC8976074</pub-id><pub-id pub-id-type="pmid">35365629</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-29366-6</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>IC</given-names></name><name><surname>Artola-Boran</surname><given-names>M</given-names></name><name><surname>Gurtner</surname><given-names>A</given-names></name><name><surname>Bertram</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Frangez</surname><given-names>Z</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name><name><surname>Yousefi</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>H-U</given-names></name><name><surname>Tzankov</surname><given-names>A</given-names></name><etal/></person-group><article-title>The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses</article-title><source>J Exp Med</source><year>2020</year><volume>217</volume><pub-id pub-id-type="pmcid">PMC7953737</pub-id><pub-id pub-id-type="pmid">32970801</pub-id><pub-id pub-id-type="doi">10.1084/jem.20190706</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurtner</surname><given-names>A</given-names></name><name><surname>Borrelli</surname><given-names>C</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>I</given-names></name><name><surname>Bach</surname><given-names>K</given-names></name><name><surname>Acar</surname><given-names>IE</given-names></name><name><surname>Núñez</surname><given-names>NG</given-names></name><name><surname>Crepaz</surname><given-names>D</given-names></name><name><surname>Handler</surname><given-names>K</given-names></name><name><surname>Vu</surname><given-names>VP</given-names></name><name><surname>Lafzi</surname><given-names>A</given-names></name><name><surname>Stirm</surname><given-names>K</given-names></name><etal/></person-group><article-title>Active eosinophils regulate host defence and immune responses in colitis</article-title><source>Nature</source><year>2023</year><volume>615</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmcid">PMC9977678</pub-id><pub-id pub-id-type="pmid">36509106</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-05628-7</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>JH</given-names></name><name><surname>Chase</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>MM</given-names></name><name><surname>Saferali</surname><given-names>A</given-names></name><name><surname>Castaldi</surname><given-names>PJ</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Hersh</surname><given-names>CP</given-names></name></person-group><article-title>Peripheral blood gene expression signatures of eosinophilic chronic obstructive pulmonary disease</article-title><source>Am J Respir Cell Mol Biol</source><year>2019</year><volume>61</volume><fpage>398</fpage><lpage>401</lpage><pub-id pub-id-type="pmcid">PMC6839929</pub-id><pub-id pub-id-type="pmid">31469299</pub-id><pub-id pub-id-type="doi">10.1165/rcmb.2019-0112LE</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartnell</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>DS</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name></person-group><article-title>CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines</article-title><source>Immunology</source><year>1993</year><volume>80</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="pmcid">PMC1422202</pub-id><pub-id pub-id-type="pmid">8262555</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Joo</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>S-C</given-names></name></person-group><article-title>NF-κB signaling in inflammation</article-title><source>Signal Transduct Target Ther</source><year>2017</year><volume>2</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC5661633</pub-id><pub-id pub-id-type="pmid">29158945</pub-id><pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejjani</surname><given-names>F</given-names></name><name><surname>Evanno</surname><given-names>E</given-names></name><name><surname>Zibara</surname><given-names>K</given-names></name><name><surname>Piechaczyk</surname><given-names>M</given-names></name><name><surname>Jariel-Encontre</surname><given-names>I</given-names></name></person-group><article-title>The AP-1 transcriptional complex: Local switch or remote command?</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2019</year><volume>1872</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">31034924</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalessi</surname><given-names>T</given-names></name><name><surname>Valenta</surname><given-names>T</given-names></name><name><surname>Moro</surname><given-names>G</given-names></name><name><surname>Brügger</surname><given-names>MD</given-names></name><name><surname>Meijs</surname><given-names>A</given-names></name><name><surname>Szczerba</surname><given-names>BM</given-names></name><name><surname>Brunner</surname><given-names>T</given-names></name><name><surname>Lampart</surname><given-names>S</given-names></name><name><surname>Nater</surname><given-names>M</given-names></name><name><surname>van den Broek</surname><given-names>M</given-names></name><name><surname>Platt</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>An oncoembryology approach uncovers SoxC-driven regulation of colon development and cancer</article-title><source>Biorxiv</source><year>2024</year></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>AR</given-names></name><name><surname>Luongo</surname><given-names>C</given-names></name><name><surname>Gould</surname><given-names>KA</given-names></name><name><surname>McNeley</surname><given-names>MK</given-names></name><name><surname>Shoemaker</surname><given-names>AR</given-names></name><name><surname>Dove</surname><given-names>WF</given-names></name></person-group><article-title>ApcMin: a mouse model for intestinal and mammary tumorigenesis</article-title><source>Eur J Cancer</source><year>1995</year><volume>31A</volume><fpage>1061</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">7576992</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NA</given-names></name><name><surname>McGarry</surname><given-names>MP</given-names></name><name><surname>Larson</surname><given-names>KA</given-names></name><name><surname>Horton</surname><given-names>MA</given-names></name><name><surname>Kristensen</surname><given-names>AB</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name></person-group><article-title>Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>1332</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">9013977</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Dan</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Dou</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><etal/></person-group><article-title>SPP1+ macrophages in colorectal cancer: Markers of malignancy and promising therapeutic targets</article-title><source>Genes Dis</source><year>2024</year><elocation-id>101340</elocation-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Skrzypczynska</surname><given-names>KM</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>O’Brien</surname><given-names>SA</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><etal/></person-group><article-title>Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>442</fpage><lpage>459</lpage><elocation-id>e29</elocation-id><pub-id pub-id-type="pmid">32302573</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>M</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name></person-group><article-title>CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes</article-title><source>Nat Protoc</source><year>2020</year><volume>15</volume><fpage>1484</fpage><lpage>1506</lpage><pub-id pub-id-type="pmid">32103204</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Dimina</surname><given-names>D</given-names></name><name><surname>Macias</surname><given-names>MP</given-names></name><name><surname>Ochkur</surname><given-names>SI</given-names></name><name><surname>McGarry</surname><given-names>MP</given-names></name><name><surname>O’Neill</surname><given-names>KR</given-names></name><name><surname>Protheroe</surname><given-names>C</given-names></name><name><surname>Pero</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Cormier</surname><given-names>SA</given-names></name><name><surname>Lenkiewicz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Defining a link with asthma in mice congenitally deficient in eosinophils</article-title><source>Science</source><year>2004</year><volume>305</volume><fpage>1773</fpage><lpage>1776</lpage><pub-id pub-id-type="pmid">15375267</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ru</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Vu</surname><given-names>T</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Mirza</surname><given-names>A</given-names></name><name><surname>Altan-Bonnet</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name><name><surname>Wakefield</surname><given-names>L</given-names></name><etal/></person-group><article-title>Systematic investigation of cytokine signaling activity at the tissue and single-cell levels</article-title><source>Nat Methods</source><year>2021</year><volume>18</volume><fpage>1181</fpage><lpage>1191</lpage><pub-id pub-id-type="pmcid">PMC8493809</pub-id><pub-id pub-id-type="pmid">34594031</pub-id><pub-id pub-id-type="doi">10.1038/s41592-021-01274-5</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Si</surname><given-names>T</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name></person-group><article-title>Tumor-associated macrophage-derived transforming growth factor-β promotes colorectal cancer progression through HIF1-TRIB3 signaling</article-title><source>Cancer Sci</source><year>2021</year><volume>112</volume><fpage>4198</fpage><lpage>4207</lpage><pub-id pub-id-type="pmcid">PMC8486199</pub-id><pub-id pub-id-type="pmid">34375482</pub-id><pub-id pub-id-type="doi">10.1111/cas.15101</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Väyrynen</surname><given-names>JP</given-names></name><name><surname>Lau</surname><given-names>MC</given-names></name><name><surname>Haruki</surname><given-names>K</given-names></name><name><surname>Väyrynen</surname><given-names>SA</given-names></name><name><surname>Dias Costa</surname><given-names>A</given-names></name><name><surname>Borowsky</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Fujiyoshi</surname><given-names>K</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Twombly</surname><given-names>TS</given-names></name><name><surname>Kishikawa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin and eosin-stained sections</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><fpage>4326</fpage><lpage>4338</lpage><pub-id pub-id-type="pmcid">PMC7442724</pub-id><pub-id pub-id-type="pmid">32439699</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0071</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>C</given-names></name><name><surname>Gurtner</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>IC</given-names></name><name><surname>Moor</surname><given-names>AE</given-names></name></person-group><article-title>Stress-free single-cell transcriptomic profiling and functional genomics of murine eosinophils</article-title><source>Nat Protoc</source><year>2024</year><volume>19</volume><fpage>1679</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">38504138</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colino-Sanguino</surname><given-names>Y</given-names></name><name><surname>Rodriguez de la Fuente</surname><given-names>L</given-names></name><name><surname>Gloss</surname><given-names>B</given-names></name><name><surname>Law</surname><given-names>AMK</given-names></name><name><surname>Handler</surname><given-names>K</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Salomon</surname><given-names>R</given-names></name><name><surname>Gallego-Ortega</surname><given-names>D</given-names></name><name><surname>Valdes-Mora</surname><given-names>F</given-names></name></person-group><article-title>Performance comparison of high throughput single-cell RNA-Seq platforms in complex tissues</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><elocation-id>e37185</elocation-id><pub-id pub-id-type="pmcid">PMC11408078</pub-id><pub-id pub-id-type="pmid">39296129</pub-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e37185</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salcher</surname><given-names>S</given-names></name><name><surname>Sturm</surname><given-names>G</given-names></name><name><surname>Horvath</surname><given-names>L</given-names></name><name><surname>Untergasser</surname><given-names>G</given-names></name><name><surname>Kuempers</surname><given-names>C</given-names></name><name><surname>Fotakis</surname><given-names>G</given-names></name><name><surname>Panizzolo</surname><given-names>E</given-names></name><name><surname>Martowicz</surname><given-names>A</given-names></name><name><surname>Trebo</surname><given-names>M</given-names></name><name><surname>Pall</surname><given-names>G</given-names></name><name><surname>Gamerith</surname><given-names>G</given-names></name><etal/></person-group><article-title>High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>1503</fpage><lpage>1520</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC9767679</pub-id><pub-id pub-id-type="pmid">36368318</pub-id><pub-id pub-id-type="doi">10.1016/j.ccell.2022.10.008</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisaru-Tal</surname><given-names>S</given-names></name><name><surname>Dulberg</surname><given-names>S</given-names></name><name><surname>Beck</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Itan</surname><given-names>M</given-names></name><name><surname>Hediyeh-Zadeh</surname><given-names>S</given-names></name><name><surname>Caldwell</surname><given-names>J</given-names></name><name><surname>Rozenberg</surname><given-names>P</given-names></name><name><surname>Dolitzky</surname><given-names>A</given-names></name><name><surname>Avlas</surname><given-names>S</given-names></name><name><surname>Hazut</surname><given-names>I</given-names></name><etal/></person-group><article-title>Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><fpage>5555</fpage><lpage>5571</lpage><pub-id pub-id-type="pmid">34429328</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreone</surname><given-names>S</given-names></name><name><surname>Spadaro</surname><given-names>F</given-names></name><name><surname>Buccione</surname><given-names>C</given-names></name><name><surname>Mancini</surname><given-names>J</given-names></name><name><surname>Tinari</surname><given-names>A</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>Gambardella</surname><given-names>AR</given-names></name><name><surname>Lucarini</surname><given-names>V</given-names></name><name><surname>Ziccheddu</surname><given-names>G</given-names></name><name><surname>Parolini</surname><given-names>I</given-names></name><name><surname>Zanetti</surname><given-names>C</given-names></name><etal/></person-group><article-title>IL-33 promotes CD11b/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><elocation-id>1664</elocation-id><pub-id pub-id-type="pmcid">PMC6895824</pub-id><pub-id pub-id-type="pmid">31717819</pub-id><pub-id pub-id-type="doi">10.3390/cancers11111664</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>F</given-names></name><name><surname>Driss</surname><given-names>V</given-names></name><name><surname>Delbeke</surname><given-names>M</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><name><surname>Hermann</surname><given-names>E</given-names></name><name><surname>Dombrowicz</surname><given-names>D</given-names></name><name><surname>Capron</surname><given-names>M</given-names></name></person-group><article-title>Human eosinophils exert TNF-α andgranzyme A-mediated tumoricidal activity towardcolon carcinoma cells</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>7443</fpage><lpage>7451</lpage><pub-id pub-id-type="pmid">21068403</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carretero</surname><given-names>R</given-names></name><name><surname>Sektioglu</surname><given-names>IM</given-names></name><name><surname>Garbi</surname><given-names>N</given-names></name><name><surname>Salgado</surname><given-names>OC</given-names></name><name><surname>Beckhove</surname><given-names>P</given-names></name><name><surname>Hämmerling</surname><given-names>GJ</given-names></name></person-group><article-title>Eosinophils orchestrate cancer rejection bynormalizing tumor vessels and enhancinginfiltration of CD8(+) T cells</article-title><source>Nat Immunol</source><year>2015</year><volume>16</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">25915731</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichman</surname><given-names>H</given-names></name><name><surname>Itan</surname><given-names>M</given-names></name><name><surname>Rozenberg</surname><given-names>P</given-names></name><name><surname>Yarmolovski</surname><given-names>T</given-names></name><name><surname>Brazowski</surname><given-names>E</given-names></name><name><surname>Varol</surname><given-names>C</given-names></name><name><surname>Gluck</surname><given-names>N</given-names></name><name><surname>Shapira</surname><given-names>S</given-names></name><name><surname>Arber</surname><given-names>N</given-names></name><name><surname>Qimron</surname><given-names>U</given-names></name><name><surname>Karo-Atar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Activated eosinophils exertantitumorigenic activities in colorectal cancer</article-title><source>Cancer Immunol Res</source><year>2019</year><volume>7</volume><fpage>388</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">30665890</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xun</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of atumour immune barrier in the HCCmicroenvironment that determines the efficacy ofimmunotherapy</article-title><source>J Hepatol</source><year>2023</year><volume>78</volume><fpage>770</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">36708811</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>MC</given-names></name><name><surname>Khan</surname><given-names>SQ</given-names></name><name><surname>Kaneda</surname><given-names>MM</given-names></name><name><surname>Pathria</surname><given-names>P</given-names></name><name><surname>Shepard</surname><given-names>R</given-names></name><name><surname>Louis</surname><given-names>TL</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>G</given-names></name><name><surname>Leem</surname><given-names>C</given-names></name><name><surname>Faridi</surname><given-names>MH</given-names></name><name><surname>Geraghty</surname><given-names>T</given-names></name><etal/></person-group><article-title>Integrin CD11b activation drivesanti-tumor innate immunity</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><elocation-id>5379</elocation-id><pub-id pub-id-type="pmcid">PMC6300665</pub-id><pub-id pub-id-type="pmid">30568188</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-07387-4</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griess</surname><given-names>B</given-names></name><name><surname>Mir</surname><given-names>S</given-names></name><name><surname>Datta</surname><given-names>K</given-names></name><name><surname>Teoh-Fitzgerald</surname><given-names>M</given-names></name></person-group><article-title>Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression</article-title><source>Free Radic Biol Med</source><year>2020</year><volume>147</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="pmcid">PMC10035558</pub-id><pub-id pub-id-type="pmid">31863907</pub-id><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.12.018</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moratal</surname><given-names>C</given-names></name><name><surname>Raffort</surname><given-names>J</given-names></name><name><surname>Arrighi</surname><given-names>N</given-names></name><name><surname>Rekima</surname><given-names>S</given-names></name><name><surname>Schaub</surname><given-names>S</given-names></name><name><surname>Dechesne</surname><given-names>CA</given-names></name><name><surname>Chinetti</surname><given-names>G</given-names></name><name><surname>Dani</surname><given-names>C</given-names></name></person-group><article-title>IL-1β- and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><elocation-id>17005</elocation-id><pub-id pub-id-type="pmcid">PMC6242986</pub-id><pub-id pub-id-type="pmid">30451963</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-35429-w</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kratochvill</surname><given-names>F</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Haverkamp</surname><given-names>JM</given-names></name><name><surname>Van de Velde</surname><given-names>L-A</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Kawauchi</surname><given-names>D</given-names></name><name><surname>McEvoy</surname><given-names>J</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Dyer</surname><given-names>MA</given-names></name><name><surname>Qualls</surname><given-names>JE</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name></person-group><article-title>TNF counterbalances the emergence of M2 tumor macrophages</article-title><source>Cell Rep</source><year>2015</year><volume>12</volume><fpage>1902</fpage><lpage>1914</lpage><pub-id pub-id-type="pmcid">PMC4581986</pub-id><pub-id pub-id-type="pmid">26365184</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.033</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Baruch Morgenstern</surname><given-names>N</given-names></name><name><surname>Rochman</surname><given-names>M</given-names></name><name><surname>Kotliar</surname><given-names>M</given-names></name><name><surname>Dunn</surname><given-names>JLM</given-names></name><name><surname>Mack</surname><given-names>L</given-names></name><name><surname>Besse</surname><given-names>J</given-names></name><name><surname>Natale</surname><given-names>MA</given-names></name><name><surname>Klingler</surname><given-names>AM</given-names></name><name><surname>Felton</surname><given-names>JM</given-names></name><name><surname>Caldwell</surname><given-names>JM</given-names></name><name><surname>Barski</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-cell RNA-sequencing of human eosinophils in allergic inflammation in the esophagus</article-title><source>J Allergy Clin Immunol</source><year>2024</year><volume>154</volume><fpage>974</fpage><lpage>987</lpage><pub-id pub-id-type="pmcid">PMC11456386</pub-id><pub-id pub-id-type="pmid">38871184</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2024.05.029</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="pmcid">PMC3919969</pub-id><pub-id pub-id-type="pmid">24071849</pub-id><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>HG</given-names></name><name><surname>Liu</surname><given-names>MC</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>FitzGerald</surname><given-names>JM</given-names></name><name><surname>Chetta</surname><given-names>A</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>LE</given-names></name><name><surname>Keene</surname><given-names>ON</given-names></name><name><surname>Yancey</surname><given-names>SW</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name></person-group><article-title>MENSA Investigators, Mepolizumab treatment in patients with severe eosinophilic asthma</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>1198</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">25199059</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>FitzGerald</surname><given-names>JM</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Nair</surname><given-names>P</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Lommatzsch</surname><given-names>M</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Barker</surname><given-names>P</given-names></name><name><surname>Sproule</surname><given-names>S</given-names></name><name><surname>Gilmartin</surname><given-names>G</given-names></name><etal/></person-group><article-title>CALIMA study investigators, Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>2128</fpage><lpage>2141</lpage><pub-id pub-id-type="pmid">27609406</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>ME</given-names></name><name><surname>Munitz</surname><given-names>A</given-names></name><name><surname>Ackerman</surname><given-names>SJ</given-names></name><name><surname>Drake</surname><given-names>MG</given-names></name><name><surname>Jackson</surname><given-names>DJ</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name><name><surname>Dougan</surname><given-names>SK</given-names></name><name><surname>Berdnikovs</surname><given-names>S</given-names></name><name><surname>Schleich</surname><given-names>F</given-names></name><name><surname>Matucci</surname><given-names>A</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Eosinophils in health and disease: A state-of-the-art review</article-title><source>Mayo Clin Proc</source><year>2021</year><volume>96</volume><fpage>2694</fpage><lpage>2707</lpage><pub-id pub-id-type="pmid">34538424</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname><given-names>LA</given-names></name><name><surname>Strath</surname><given-names>M</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name><name><surname>Sanderson</surname><given-names>CJ</given-names></name></person-group><article-title>Eosinophilia in transgenic mice expressing interleukin 5</article-title><source>J Exp Med</source><year>1990</year><volume>172</volume><fpage>1425</fpage><lpage>1431</lpage><pub-id pub-id-type="pmcid">PMC2188679</pub-id><pub-id pub-id-type="pmid">2230651</pub-id><pub-id pub-id-type="doi">10.1084/jem.172.5.1425</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roper</surname><given-names>J</given-names></name><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Akkad</surname><given-names>A</given-names></name><name><surname>Almeqdadi</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>SB</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Yilmaz</surname><given-names>ÖH</given-names></name></person-group><article-title>Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation</article-title><source>Nat Protoc</source><year>2018</year><volume>13</volume><fpage>217</fpage><lpage>234</lpage><pub-id pub-id-type="pmcid">PMC6145089</pub-id><pub-id pub-id-type="pmid">29300388</pub-id><pub-id pub-id-type="doi">10.1038/nprot.2017.136</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>1190</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">23744940</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC3530905</pub-id><pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Kowalski</surname><given-names>MH</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Madad</surname><given-names>S</given-names></name><name><surname>Fernandez-Granda</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><article-title>Dictionary learning for integrative, multimodal and scalable single-cell analysis</article-title><source>Nat Biotechnol</source><year>2024</year><volume>42</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="pmcid">PMC10928517</pub-id><pub-id pub-id-type="pmid">37231261</pub-id><pub-id pub-id-type="doi">10.1038/s41587-023-01767-y</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Corbett</surname><given-names>SE</given-names></name><name><surname>Koga</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>JD</given-names></name></person-group><article-title>Decontamination of ambient RNA in single-cell RNA-seq with DecontX</article-title><source>Genome Biol</source><year>2020</year><volume>21</volume><fpage>57</fpage><pub-id pub-id-type="pmcid">PMC7059395</pub-id><pub-id pub-id-type="pmid">32138770</pub-id><pub-id pub-id-type="doi">10.1186/s13059-020-1950-6</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D</given-names></name><name><surname>Looney</surname><given-names>AP</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>E</given-names></name><name><surname>Fong</surname><given-names>V</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Chak</surname><given-names>S</given-names></name><name><surname>Naikawadi</surname><given-names>RP</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name><name><surname>Abate</surname><given-names>AR</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="pmcid">PMC6340744</pub-id><pub-id pub-id-type="pmid">30643263</pub-id><pub-id pub-id-type="doi">10.1038/s41590-018-0276-y</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>TSP</given-names></name><name><surname>Painter</surname><given-names>MW</given-names></name></person-group><article-title>Immunological Genome Project Consortium, The Immunological Genome Project: networks of gene expression in immune cells</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novershtern</surname><given-names>N</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Lawton</surname><given-names>LN</given-names></name><name><surname>Mak</surname><given-names>RH</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name><name><surname>McConkey</surname><given-names>ME</given-names></name><name><surname>Habib</surname><given-names>N</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Densely interconnected transcriptional circuits control cell states in human hematopoiesis</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>296</fpage><lpage>309</lpage><pub-id pub-id-type="pmcid">PMC3049864</pub-id><pub-id pub-id-type="pmid">21241896</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2011.01.004</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Alvarado</surname><given-names>LJ</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Lehmann</surname><given-names>ML</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>B-H</given-names></name><name><surname>Larochelle</surname><given-names>A</given-names></name><name><surname>Kelsall</surname><given-names>BL</given-names></name></person-group><article-title>Commensal microbiota drive the functional diversification of colon macrophages</article-title><source>Mucosal Immunol</source><year>2020</year><volume>13</volume><fpage>216</fpage><lpage>229</lpage><pub-id pub-id-type="pmcid">PMC7039809</pub-id><pub-id pub-id-type="pmid">31772323</pub-id><pub-id pub-id-type="doi">10.1038/s41385-019-0228-3</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PM</given-names></name><name><surname>Garrett</surname><given-names>WS</given-names></name></person-group><article-title>The gut microbiota and mucosal T cells</article-title><source>Front Microbiol</source><year>2011</year><volume>2</volume><fpage>111</fpage><pub-id pub-id-type="pmcid">PMC3153059</pub-id><pub-id pub-id-type="pmid">21833339</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2011.00111</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>G-Y</given-names></name><name><surname>Giles</surname><given-names>DA</given-names></name><name><surname>Kronenberg</surname><given-names>M</given-names></name></person-group><article-title>The role of innate lymphoid cells in response to microbes at mucosal surfaces</article-title><source>Mucosal Immunol</source><year>2020</year><volume>13</volume><fpage>399</fpage><lpage>412</lpage><pub-id pub-id-type="pmcid">PMC7186215</pub-id><pub-id pub-id-type="pmid">32047273</pub-id><pub-id pub-id-type="doi">10.1038/s41385-020-0265-y</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzén</surname><given-names>O</given-names></name><name><surname>Gan</surname><given-names>L-M</given-names></name><name><surname>Björkegren</surname><given-names>JLM</given-names></name></person-group><article-title>PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data</article-title><source>Database</source><year>2019</year><volume>2019</volume><pub-id pub-id-type="pmcid">PMC6450036</pub-id><pub-id pub-id-type="pmid">30951143</pub-id><pub-id pub-id-type="doi">10.1093/database/baz046</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilionis</surname><given-names>R</given-names></name><name><surname>Engblom</surname><given-names>C</given-names></name><name><surname>Pfirschke</surname><given-names>C</given-names></name><name><surname>Savova</surname><given-names>V</given-names></name><name><surname>Zemmour</surname><given-names>D</given-names></name><name><surname>Saatcioglu</surname><given-names>HD</given-names></name><name><surname>Krishnan</surname><given-names>I</given-names></name><name><surname>Maroni</surname><given-names>G</given-names></name><name><surname>Meyerovitz</surname><given-names>CV</given-names></name><name><surname>Kerwin</surname><given-names>CM</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1317</fpage><lpage>1334</lpage><elocation-id>e10</elocation-id><pub-id pub-id-type="pmcid">PMC6620049</pub-id><pub-id pub-id-type="pmid">30979687</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.009</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><fpage>60</fpage><pub-id pub-id-type="pmcid">PMC8882672</pub-id><pub-id pub-id-type="pmid">35221332</pub-id><pub-id pub-id-type="doi">10.1038/s41392-022-00881-8</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Policastro</surname><given-names>RA</given-names></name><name><surname>Sriramkumar</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>T</given-names></name><name><surname>Huntington</surname><given-names>TD</given-names></name><name><surname>Ladaika</surname><given-names>CA</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Hao</surname><given-names>C</given-names></name><name><surname>Zentner</surname><given-names>GE</given-names></name><name><surname>O’Hagan</surname><given-names>HM</given-names></name></person-group><article-title>LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><fpage>3791</fpage><lpage>3805</lpage><pub-id pub-id-type="pmcid">PMC8513805</pub-id><pub-id pub-id-type="pmid">34035083</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-3562</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotkevich</surname><given-names>G</given-names></name><name><surname>Sukhov</surname><given-names>V</given-names></name><name><surname>Budin</surname><given-names>N</given-names></name><name><surname>Shpak</surname><given-names>B</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name></person-group><article-title>Fast gene set enrichment analysis</article-title><source>bioRxiv</source><year>2016</year><elocation-id>060012</elocation-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Pinchback</surname><given-names>R</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="pmcid">PMC3106198</pub-id><pub-id pub-id-type="pmid">21546393</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmcid">PMC1239896</pub-id><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aibar</surname><given-names>S</given-names></name><name><surname>González-Blas</surname><given-names>CB</given-names></name><name><surname>Moerman</surname><given-names>T</given-names></name><name><surname>Huynh-Thu</surname><given-names>VA</given-names></name><name><surname>Imrichova</surname><given-names>H</given-names></name><name><surname>Hulselmans</surname><given-names>G</given-names></name><name><surname>Rambow</surname><given-names>F</given-names></name><name><surname>Marine</surname><given-names>J-C</given-names></name><name><surname>Geurts</surname><given-names>P</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>van den Oord</surname><given-names>J</given-names></name><etal/></person-group><article-title>SCENIC: single-cell regulatory network inference and clustering</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>1083</fpage><lpage>1086</lpage><pub-id pub-id-type="pmcid">PMC5937676</pub-id><pub-id pub-id-type="pmid">28991892</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4463</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh-Thu</surname><given-names>VA</given-names></name><name><surname>Irrthum</surname><given-names>A</given-names></name><name><surname>Wehenkel</surname><given-names>L</given-names></name><name><surname>Geurts</surname><given-names>P</given-names></name></person-group><article-title>Inferring regulatory networks from expression data using tree-based methods</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><pub-id pub-id-type="pmcid">PMC2946910</pub-id><pub-id pub-id-type="pmid">20927193</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012776</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C-H</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name></person-group><article-title>ggVennDiagram: An Intuitive, Easy-to-Use, and Highly Customizable R Package to Generate Venn Diagram</article-title><source>Front Genet</source><year>2021</year><volume>12</volume><elocation-id>706907</elocation-id><pub-id pub-id-type="pmcid">PMC8452859</pub-id><pub-id pub-id-type="pmid">34557218</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2021.706907</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C-H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Akyol</surname><given-names>T</given-names></name><name><surname>Dusa</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name></person-group><article-title>ggVennDiagram: Intuitive Venn diagram software extended</article-title><source>Imeta</source><year>2024</year><volume>3</volume><fpage>e177</fpage><pub-id pub-id-type="pmcid">PMC10989133</pub-id><pub-id pub-id-type="pmid">38868514</pub-id><pub-id pub-id-type="doi">10.1002/imt2.177</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Schilder</surname><given-names>BM</given-names></name><name><surname>Skene</surname><given-names>NG</given-names></name></person-group><source>“orthogene: An R Package for Easy Mapping of Orthologous Genes across Hundreds of Species</source><year>2022</year></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="pmcid">PMC3159387</pub-id><pub-id pub-id-type="pmid">19617889</pub-id><pub-id pub-id-type="doi">10.1038/nprot.2009.97</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><source>ggplot2: elegant graphics for data analysis</source><publisher-loc>New York</publisher-loc><publisher-name>Springer-Verlag</publisher-name><year>2016</year><fpage>2009</fpage><comment>Book [Preprint]</comment></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name></person-group><article-title>Complex heatmap visualization</article-title><source>Imeta</source><year>2022</year><volume>1</volume><fpage>e43</fpage><pub-id pub-id-type="pmcid">PMC10989952</pub-id><pub-id pub-id-type="pmid">38868715</pub-id><pub-id pub-id-type="doi">10.1002/imt2.43</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>Characterisation of human eosinophils in colorectal cancer at single cell resolution.</title><p>(<bold>A</bold>) MBP-1<sup>+</sup> eosinophils as a proportion of DAPI<sup>+</sup> cells on human tissue microarrays, across increasing CRC stages (I n = 11, II n = 25, III n = 4 slides). (<bold>B</bold>) A-Eos frequencies (co-localization of MBP-1<sup>+</sup> and PD-L1<sup>+</sup> signal) in normal adjacent tissue (NAT), adenoma and adenocarcinoma on tissue microarrays (NAT n = 24, adenoma n = 6, adenocarcinoma n = 28 slides). (<bold>C</bold>) Immunofluorescence images of tissue microarrays from NAT (left) and adenocarcinoma (right). Eosinophils are represented in green (stained for MBP-1), with PD-L1 expression in red and DAPI in blue. Scale bar: 100 μm. (<bold>D</bold> and <bold>E</bold>) UMAP of the integrated tumor, NAT and blood healthy eosinophils. The color represents the gene expression level of selected marker genes (D) and different clusters (E). (<bold>F</bold>) Barplot (left) indicating proportions of clusters within different tissues. Statistical analysis between tumor and NAT shown in a point-range plot (right) [Permutation test, Benjamini Hochberg adjusted p-values, ns (non significant), Log2FD (log2 fold difference)]. (<bold>G</bold>) Bubble plot displaying the average gene expression of selected DEGs (differentially expressed genes) per cluster. All genes are significant (p.adj ≤ 0.05, Log2 Fold Change &gt; 0.25 or &lt; -0.25). (<bold>H</bold>) Heatmap showing the regulon activity of selected regulons from SCENIC analysis of each cluster. (<bold>I</bold>) Volcano plot of DEGs between NAT and tumor eosinophils from cluster Eos_H2. Red dots represent significantly up- and down-regulated genes (p.adj ≤ 0.05, Log2 Fold Change &gt; 0.25 or &lt; -0.25). Selected genes are highlighted. (<bold>J</bold>) Bubble plot indicating enriched GO (gene ontology) terms in Eos_H2 compared to the Eos_H1. The x-axis displays the normalized enrichment score and the size shows p.adj (null hypothesis testing and Benjamini-Hochberg correction). (<bold>K</bold>) Violin plot depicting the MHC-I and antigen processing score between Eos_H1 and Eos_H2 eosinophils (two-sided Wilcoxon Rank-Sum test). (A, B) One-Way ANOVA. (A, B, K) Mean ± standard deviation are indicated; stars indicate significance of the p-value (* &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001, **** &lt; 0.0001). (D-K) Tumor and NAT n = 7, blood healthy n = 6 samples. (G, I) DEG analysis: non-parametric Wilcoxon Rank-Sum Test and Bonferroni correction of p-values. (B-K) NAT: normal adjacent tissue. (F, G, I, J) P.adj: p-value adjusted.</p></caption><graphic xlink:href="EMS202316-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Mouse colorectal cancer eosinophils and their comparison to the human counterparts.</title><p>(<bold>A</bold>) Macroscopic (left) and histological H&amp;E (hematoxylin and eosin) (right) image of the AKPS tumor. Scale bar: 1 mm. (<bold>B</bold>) Absolute counts of eosinophils in normal adjacent tissue (NAT) and AKPS tumors after 4 and 6 weeks (NAT and AKPS 4 weeks n = 6, NAT and AKPS 6 weeks n = 5 samples). (<bold>C</bold>) A-Eos frequencies in NAT, Apc<sup>min/+</sup>, and AKPS tumors (NAT n = 13, Apc<sup>min/+</sup> n = 7, AKPS tumor n = 5 samples). (<bold>D</bold>) Absolute counts of eosinophils in NAT and Apc<sup>min/+</sup> (NAT n = 19, Apc<sup>min/+</sup> n = 7 samples). Unpaired t-test. (<bold>E</bold>) UMAP of integrated tumor eosinophils with eosinophils from non-tumor bearing <italic>Il5-tg</italic> (<italic>Il5-</italic>transgenic) BM (bone marrow), blood and colon (<xref ref-type="bibr" rid="R14">14</xref>). Colors represent eosinophil subtypes (left) and tumor derived eosinophils (right). (<bold>F</bold>) Eosinophils subtype proportions between different conditions. (<bold>G</bold>) Volcano plot depicting DEGs (differentially expressed genes) between eosinophils from control and tumor. Significantly enriched or depleted genes are highlighted in red (p-value adjusted ≤ 0.05, Log2 Fold Change &gt; 0.25 or &lt; -0.25, non-parametric Wilcoxon Rank-Sum test, Bonferroni correction of p-values). Selected DEGs are highlighted. (<bold>H</bold>) Bubble plot indicating enriched GO (gene ontology) terms in tumor eosinophils compared to the control. The x-axis displays the normalized enrichment score and the size shows the adjusted p-value (p.adj., null hypothesis testing and Benjamini-Hochberg correction. (<bold>I</bold>) Violin plot of the MHC-I and antigen processing score between control and tumor eosinophils. (<bold>J</bold>) Violin plots highlighting mouse eosinophilic subtype scores (left: B-Eos, right: A-Eos) within human eosinophil clusters. (<bold>K</bold>) UMAP of human eosinophils colored by annotated subtypes (left) and a barplot showing their proportions within different tissues (right). (B,C) One-Way ANOVA. (B-D, I, J) Mean ± standard deviation are indicated; stars indicate significance of the p-value (* &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001, **** &lt; 0.0001, ns non-significant). (E-I) Control and tumor n = 5 samples. (I, J) Two-sided Wilcoxon Rank-Sum test. (J, K) Tumor and NAT n = 7, blood healthy n = 6 samples. (B-D, J, K) NAT: normal adjacent tissue.</p></caption><graphic xlink:href="EMS202316-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Analysis of immune cells from the tumor immune network in human and mouse colorectal cancer.</title><p>(<bold>A</bold>) UMAP of CD45<sup>+</sup> cell type populations from control and tumor of human (left) and mouse (right) data. Colors represent annotated cell types. (<bold>B</bold>) Barplots comparing cell type proportions from human (left) and mouse (right) data. NAT: normal adjacent tissue. (<bold>C</bold>) Barplots of selected cell types comparing control and tumor of human (left) and mouse (right) datasets. Stars indicate statistical significance (adjusted p-value ≤ 0.05 and Log2 Fold Difference &gt; 0.5 or &lt; -0.5, permutation test, Benjamini-Hochberg p-value adjustment). (<bold>D</bold>) Total number of significant L-R (ligand-receptor) interactions between eosinophils and any other cell type within tumors (upper plot: human; lower plot: mouse). L-R interactions were predicted using the CellPhoneDB algorithm and database (null hypothesis testing, p-value ≤ 0.05). Both directionalities (ligand-receptor and receptor-ligand) were considered. (A-D) TAMs: Tumor associated macrophages, B: B cells, T: T cells, Eos: Eosinophils, PCs: Plasma cells, DCs: Dendritic cells, ILCs: Innate lymphoid cells, TRMs: Tissue resident macrophages. Tumor and NAT from human datasets n = 7, tumor and control from mouse datasets n = 5 samples.</p></caption><graphic xlink:href="EMS202316-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Eosinophil deficiency drives tumor metastasis and the expansion of SPP1<sup>+</sup> TAMs.</title><p>(<bold>A</bold>) Macroscopic images of AKPS primary tumors from WT and PHIL mice, taken at the endpoint of 6 weeks. (<bold>B</bold>) Tumor weights (upper left) and volumes (upper right), percentage of eosinophils in the blood (bottom left) and tumor (bottom right) from AKPS tumor-bearing mice (n = 5 samples each). (<bold>C</bold>) The incidence rate (upper) and counts (bottom) of peritoneal metastasis in mice bearing primary AKPS tumors (WT n = 4, PHIL n = 2). Mets: metastasis. Two-tailed Fisher’s exact tests (upper plot). (<bold>D</bold>) Image of a PHIL mouse injected with AKPS organoids. Red arrows point to metastasis in the peritoneal cavity. (<bold>E</bold>) Bar plots of eosinophils (left) and SPP1<sup>+</sup> TAMs (right) comparing the proportions between WT and PHIL from different tissues. Stars indicate statistical significance [adjusted p-value ≤ 0.05 and Log2 Fold Difference &gt; 0.5, ns (non-significant), permutation test, Benjamini-Hochberg p-value adjustment]. WT control and tumor n = 5, PHIL control and tumor n = 2, WT peritoneal mets = 3, PHIL peritoneal mets = 6 samples. (<bold>F</bold>) Selected DEGs (differentially expressed genes) between SPP1<sup>+</sup> TAMs from PHIL and WT tumors. The Average log2 fold change (Avg. log2FC) is indicated on the y-axis. Genes are all significant (p-value adjusted ≤ 0.05); non-parametric Wilcoxon Rank-Sum test and Bonferroni correction of p-values. WT control and tumor n = 5, PHIL control and tumor n = 2 samples. (<bold>G</bold>) Relative gene expression to house-keeping gene <italic>Hprt</italic> of <italic>Vegfa</italic> and <italic>Mmp9</italic> in whole AKPS tumor tissue from WT vs PHIL mice, as determined by RT-qPCR (n = 4 samples each). (B, C bottom) Unpaired t-test, mean ± standard deviation is indicated. (B, C, E, G) stars indicate significance of the p-value (* &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001, **** &lt; 0.0001).</p></caption><graphic xlink:href="EMS202316-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Eosinophils restrict the differentiation of SPP1<sup>+</sup> macrophages <italic>in vitro</italic>.</title><p>(<bold>A</bold>-<bold>C</bold>) A-Eos proportion (A left), Mean Fluorescence Intensity (MFI) of Siglec-F (SigF) (A right), SSC-A (B left) and CD11b (B right), proportion of mouse eosinophils that are positive for CD63 (C left) and β2 integrin (C right) from eosinophils alone and upon co-culture with AKP and AKPS tumor organoids (Eos n = 6, Eos<sup>AKP</sup> and Eos<sup>AKPS</sup> n = 5 samples). (<bold>D</bold> and <bold>E</bold>) <italic>Spp1</italic> gene expression relative to <italic>Gapdh</italic> (D) and (E) the proportion of double positive (CD206 and CD13) macrophages of murine bone-marrow derived macrophages alone (Mac) and conditioned with AKPS-sup (supernatant) or TGFβ+IL-10 (n = 5 samples each). (<bold>F</bold>) Bubble plot displaying the average gene expression of <italic>Il10</italic> and <italic>Tgfβ1</italic> within annotated mouse scRNAseq data (WT control and tumor n = 5, PHIL control and tumor n = 2, WT peritoneal mets n = 3, PHIL peritoneal mets n = 6 samples). (<bold>G</bold>) <italic>Il10</italic> (left) and <italic>Tgfβ1</italic> (right) gene expression relative to <italic>Hprt</italic> from WT and PHIL whole tumor AKPS tissue (WT n = 10, PHIL n = 7 samples). (<bold>H-J</bold>) CD206<sup>+</sup> CD13<sup>+</sup> subsets (H) and representative flow cytometry plots (I), and LAP (TGF-β1)<sup>+</sup> (J) subsets as a proportion of total macrophages upon preconditioning with TGFβ+IL-10 and additional co-culture with eosinophils (Eos) with and without pretreatment with AKPS supernatant (n = 5 samples each). (A-E, G, H, J) Unpaired t-test for groups of 2, and One-Way ANOVA for groups of 3. Mean ± standard deviation is indicated; stars indicate significance of the p-value (* &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001, **** &lt; 0.0001, ns non-significant).</p></caption><graphic xlink:href="EMS202316-f005"/></fig></floats-group></article>